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Abstract 
 
Section I 
Over the last decades, the classic “one disease-one target” drug discovery approach has encountered 
new challenges by newly established concepts of drug design. Numerous disease systems are 
generally characterized by disregulation of multiple biological pathways; this observation fosters the 
formation of “multifactorial disease” concept. Several efforts were devoted to integrate the complex 
disease systems to drug discovery process. A new strategy was identified and defined as 
polypharmacology, which is the treatment of diseases by modulating their multiple targets. In 
particular, the more recently consolidated “multitarget ligands” (MLs) drug design, designated for 
the first time by Morphy et al., proposed the development of single chemical entities capable of 
simultaneously modulating multiple targets to achieve the desired therapeutic effect. 
Alzheimer’s disease (AD) is a neurodegeneration disorder, defined as multifactorial disease for the 
reason of multiple pathogenesis pathways involved in the disease onset and progress; in fact, it is 
correlated with protein misfolding which leads to hallmarks such as amyloid plaques and 
neurofibrillary tangles, as well as with events including oxidative stress. The event of oxidative stress 
in AD promotes amyloid-β (Aβ) toxicity and has been proved to increase tau hyperphosphorylation, 
through a mechanism involving GSK3β as a key enzyme. In addition, AD has been correlated with 
disfunctions at epigenetic level, involving a set of epigenetic factors as causes of its pathogenesis, 
including the histone deacetylases. Among numerous potential AD targets, transglutaminase 2 (TG2) 
is one of the most recently identified targets, given its overexpression observed in this 
neurodegenerative disease. Being responsible of protein cross-linking reactions, TG2 may play an 
important role in disfunction of proteins, such as Aβ and protein tau. Moreover, TG2 has been 
colocalized with AD hallmarks in samples of both animal and human origins. Thus, TG2 inhibitors 
could represent a promising therapeutic agent for AD’s treatment. 
This section illustrates the drug design and development of multitarget ligands targeting 
simultaneously TG2 and other targets/events implicated in AD’s pathology: a core structure of TG2 
inhibitor was taken into consideration and coupled to hydroxamic acid moiety to give potential TG2-
HDAC dual inhibitors; by merging the same core structure to the polyphenol moiety of 
hydroxicinnamic acid derivatives, potential TG2 inhibitors bearing antioxidant activity have been 
developed. The first series of compounds showed interesting activity profile in in vitro assays, with 
compound 3 being a low micromolar inhibitor of TG2 and good inhibitor for HDACs. The series of 
antioxidants were additionally evaluated for their potential inhibition toward GSK3β and amyloid 
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aggregation, and compound 22 turned out to be the most promising derivative with good antioxidant 
activity and a balanced inhibition profile on both GSK3β and Aβ self-induced aggregation.  
At the attempt of achieving a further elucidation of TG2’s role in AD, fluorescent probes targeting 
this enzyme could offer a glimpse into the complexity of this disease. Thus, fluorophores have been 
conjugated to TG2 inhibitors to construct probes for cell fluorescence imaging studies.  
 
Section II 
 
Coat protein I (COPI) is a protein complex referred to as coatomer complex. It represents the major 
component of vesicles that mediate the retrograde transport from endoplasmic reticulum to the Golgi 
apparatus in eukaryotic cells. In the absence of COPI, cells experience Golgi fragmentation, 
immature autophagosome accumulation, and ultimately death. A recent function-based genomic 
screen identified COPZ1, a gene encoding the coatomer complex subunit ζCOP1, as a promising 
cancer target. In fact, COPZ1 knockdown using siRNA causes tumor-specific growth inhibition 
without affecting the viability of normal cells. The mechanism of the tumor selectivity of COPZ1 
knockdown was explained by remarkably reduced mRNA levels of ζCOP2, a functionally redundant 
isoform of ζCOP1. As a result, while normal COPZ2-expressing cells survive COPZ1 depletion, 
COPZ2-deficient tumor cells are killed by COPZ1 knockdown. Therefore, a correct function of 
ζCOP1 is crucial for the survival of tumor cells and could be a promising target for the development 
of anticancer drugs. Compounds capable of interfering with the function of ζCOP1, by inhibiting the 
association of ζCOP1 to the coatomer complex, could exert selective antitumor activity. Since the 
main function of ζCOP1 is to form a dimer with γCOP1 within the coatomer complex, disrupters of 
this ζCOP1/γCOP1 protein-protein interaction (PPI) could impair the correct function of ζCOP1, 
thus, being potential anticancer drugs. 
Therefore, a cyclic peptide-based compound was designed from in silico studies of the interface 
ζCOP1/γCOP1 as potential disrupter of this PPI; moreover, a library of compounds was docked in 
silico to critical areas of the interface and a series of potential small-molecule disrupters of this PPI 
were identified. 
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SECTION I 
 
 Transglutaminase 2 inhibitors based multitarget ligands 
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1. Introduction 
 
 
Transglutaminase 2 (TG2, tissue transglutaminase) is the most well studied and biologically 
characterized enzymatic isoform within the transglutaminase family. In addition to its role as Ca
2+
-
dependent catalyst of post-translational modification of proteins, TG2 plays a role in a number of 
diseases, such as celiac sprue, Alzheimer’s disease, Huntington’s disease and certain types of cancer. 
In particular, numerous evidences from both in vitro and in vivo studies support the hypothesis that 
TG2 is involved in the complex pathogenesis of Alzheimer’s disease (AD). AD is considered a 
multifactorial disease and a more appropriate approach for its therapy is based on the design of new 
multitarget ligands able to interact with the different pathological targets which characterize AD. 
Hence, potent and selective TG2 inhibitors may provide important indications concerning the 
chemical features of phamarcophores potentially useful for designing multitarget ligands as new 
therapeutic agents against AD.  
 
1.1 Functions of transglutaminase 2 
Transglutaminases were discovered in 1950s as enzymes that catalyze the post-translational 
modification of proteins by the formation of isopeptide bond. To date, nine members have been 
characterized within the transglutaminase family, including transglutaminases 1-7, factor XIII A and 
erythrocyte-band4.2, which prevalently exert functions in blood clotting, wound healing, cell 
envelope formation, cell matrix stabilization and epidermal differentiation. TG2 is one of these nine 
members and is one of the most  investigated and biologically characterized isoform, being the most 
frequently occurring member in eukaryotes and present in almost all mammalian cells. As main 
catalytic activity, TG2 is able to catalyze the Ca
2+
-dependent modification of protein-bound 
glutamine side chain. In the presence of calcium, the ɤ-glutaminyl side chain of a protein is acylated 
by active site cysteine (Cys
277
) of TG2 to form a thioester intermediate with the release of ammonia. 
The intermediate thioester is attacked by a primary amine, being either a small molecule amine or the 
ɛ-amino group of protein-bound lysine residue1. This trans-amidation reaction results in the 
formation of a relatively stable isopeptide bond. TG2 can catalyze also a deamination reaction, where 
water acts as nucleophile with the consequent conversion of glutamine into glutamate
2
.  
Given the abundance of glutamine and lysine residues on the proteins in an organism, those residues 
represent the most important substrate for TG2
3
. Therefore, the enzymatic activity is tightly 
regulated by different mechanisms to prevent an excessive protein aggregation through crosslinking 
reaction. Guanosine triphosphate (GTP) and guanosine diphosphate (GDP) can both bind to TG2 and 
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inhibit the transamidase activity
4
, whereas calcium ionophores capable of transporting free calcium 
across cell membrane can increase intracellular calcium levels enough to activate intracellular TG2 
which is enzymatically latent under physiological conditions
5
. Nitric oxide can abolish the 
transamidase activity through Ca
2+
-dependent S-nitrosylation of multiple cysteine residues
6
.  
 
 
Figure 1. TG2 transamidation and deamidation catalytic mechanism
7
. 
 
Under physiological conditions, intracellular TG2 exists in its inactive conformation, due to the low 
intracellular Ca
2+
 concentration. During situations of unbalanced Ca
2+
 homeostasis, such as apoptosis 
or wound healing, TG2 undergoes rapid activation upon binding of Ca
2+
 ions. It has been suggested 
that activated cytosolic TG2 may crosslink intracellular proteins to prevent them from spilling out of 
a dying cell and causing inflammation
8
. In the extracellular environment, TG2 is mainly 
transamidase-inactive despite the presence of Ca
2+
. In the extracellular environment, TG2 once 
associated with cell surface integrin and fibronectin, can transmit signals to intracellular environment 
affecting cell adhesion, migration and signaling functions, through a mechanism independent of 
crosslinking activity
9
. 
TG2 has been well characterized by X-ray crystallography, in particular in conformations bound with 
GDP
10
 and with a peptidic inhibitor
11
. It consists of four distinct domains: 1) N-terminal containing 
the fibronectin binding site, 2) catalytic core containing the substrate binding pocket and catalytic 
triad, 3) a β-barrel domain with binding pocket for GTP and interaction site with α1 adrenergic 
receptor, 4) C-terminal containing interaction site with phospholipase. This multidomain structure 
reflects diverse catalytic activities and signaling pathways in which TG2 is involved. 
The crystal structures confirm the existence of at least two conformations for TG2: the “closed” ones 
and the “open” ones. In fact, the binding of GTP or inhibitors to TG2 causes significant 
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conformational shifts. Although it is clear that multiple TG2 conformations exist, few information is 
available about the biological relevance of each conformation.  
                        
Figure 2. X-ray crystal structures of two conformations (open and closed) of human TG2 in complex with GDP in β1-
barrel (A) and with peptidic inhibitor in the active site (B)
11
. 
 
 
1.2 Transglutaminase 2- Implications in human diseases 
TG2 is implicated in a number of human diseases, such as celiac sprue, neurodegenerative disorders, 
diabetes, liver cirrhosis, fibrosis and certain types of cancer. Importantly, the pathology or etiology 
of most of the aforementioned diseases is likely ascribable to the enzymatic function of TG2.  
Celia sprue is an autoimmune disease characterized by an impairment of the small intestine caused 
by a class of digestion-resistant proteins called prolamines, characterized by high content of proline 
and glutamine. TG2 exerts two main functions in the disease pathogenesis: 1) the enzyme 
deaminates specific glutamine residues in the prolamine proteins leading to an increased binding 
affinities of these proteins to the human leukocyte antigen (HLA) serotypes, which mediate the T-
cell response
12
; 2) The covalent complex TG2-prolamine can finally lead to an autoimmune response 
by generation of anti-TG 2 antibodies
13
.  
There is accumulating evidence that TG2 contributes to the process of cataractogenesis in the eye, 
through cross-linking of crystallins, the proteins constituting the eye lens, leading to lens 
opacification and cataract. This seems to correlate with the formation of bis(γ-glutamyl)spermidine 
cross-links between the crystallin proteins
14
.  
A
 A  
B 
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A number of experimental observations support the hypothesis that TG2 is implicated in tumor 
progression. Multiple studies showed that TG2 protein is up-regulated in various cancerous tissues 
including pancreatic carcinoma
15
, breast carcinoma
16
 and malignant melanoma
17
. A positive 
correlation between the drug resistance and metastatic potential of certain cancers with TG2 
expression levels has been demonstrated. A unifying molecular mechanism that explains the way 
how TG2 promotes oncogenesis has not been discovered. At this regard, there are mainly two 
hypotheses: first, TG2 causes activation of nuclear factor κB (NF-κB) probably through a 
crosslinking reaction, thus, consequently promotes expression of anti-apoptotic proteins, such as Bcl-
xL; second, TG2 activates the focal adhesion kinase (FAK) with the subsequent activation of anti-
apoptotic pathways, such as the P13K/Akt pathway. Furthermore, in a recent study on cancer cell-
derived microvesicles, TG2 was shown to play a role in the communication between tumor cells and 
with normal cells, by inducing transformed characteristic of cancer cells onto normal fibroblasts 
through the release of microvesicles
18
.  
The hallmarks of several neurodegenerative disorders are extensive neuronal loss and progressive 
formation of insoluble protein aggregates in the affected cerebral regions, such as amyloid plaques 
and neurofibrillary tangles in Alzheimer’s disease, Lewy bodies in Parkinson diseases and huntingtin 
protein in the homonymous disease. Importantly, all of the disease-related proteins in the 
aforementioned disorders are good substrates of TG2 in vitro
19
. Furthermore, it has been proven that 
both TG2 and its transamidase activity are increased in the affected cerebral regions of persons 
suffering from these disorders
20
. These observations suggest that TG2 may be significantly involved 
in the pathogenesis of neurodegenerative diseases.  
 
 
1.3 Transglutaminase 2 and Alzheimer’s disease 
Protein misfolding and the formation of insoluble protein complexes play a central role in the 
pathogenesis of Alzheimer's disease (AD), characterized by the aggregation of amyloid-β (Aβ) 
protein in cerebral tissue as senile plaques and the hyperphosphorilation of protein tau as 
neurofibrillary tangles
21
. However, the underlying mechanisms that trigger the misfolding of self-
interacting proteins that eventually results in formation of neurotoxic aggregates remain unclear. 
Elucidation of the driving forces of protein complex formation in AD has crucial importance for the 
development of therapies for this disease.  
Accumulating evidences support the hypothesis that TG2 may be involved in the abnormal protein 
aggregation observed in AD. As aforementioned, TG2 is a calcium-dependent enzyme that induces 
the formation of covalent γ-glutamyl-ε-lysine isopeptide bonds, which results in protein cross-links. 
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TG2-catalyzed cross-linking induces stable and protease-resistant protein complexes. Inhibition of 
TG2-catalyzed cross-linking counteracts the formation of protein aggregates, as observed in disease-
models of other protein misfolding diseases, in particular, Parkinson's and Huntington's diseases
19b
. 
With regard to AD, there is compelling evidence from in vitro studies, as well as from studies on 
postmortem human brain tissue of AD patients and animal models that demonstrates a crucial role 
for TG2 in AD pathology: 
1) Aβ and protein tau are good substrates for transglutaminase 2.  In AD, Aβ shifts from soluble 
monomers to toxic oligomers and eventually forms insoluble mature fibrils. Brain 
transglutaminases could play a role in the Aβ accumulation. Using a synthetic partial-length of Aβ 
protein, Ikura et al. demonstrated that this peptide was subject to transamidation catalyzed by 
transglutaminase resulting in formation of multimeric peptides. The same experiment showed that 
in the presence of EDTA which chelates calcium ions, multimeric peptides were not produced and 
the monomer peptide remained unchanged
22
. Protein tau is a microtubule-binding phosphoprotein 
and functionally regulated by site-specific phosphorylation. In regard to the correlation between 
TG2 activity and protein tau aggregates, it has been reported that bovine tau protein is an 
excellent substrate for TG2 through the polyamine incorporation assays, whereas recombinant 
human tau presents different levels of affinity toward TG2 based on isoform types. This study 
also demonstrated that TG2-catalyzed cross-links on protein tau is specific only for a small 
number of glutamine residues, in fact, only few segments on tau are susceptible to the 
modification induced by the enzyme
23
. Additionally, a study that used co-immunoprecipitation 
and immunocytochemistry methods confirmed the actual interaction between TG2 and protein tau 
and their colocalization at intracellular levels
24
. 
2) TG2 levels in cerebrospinal fluid are increased in AD. In vivo analysis of cerebrospinal fluid 
(CSF) in patients affected by AD has revealed that the levels of TG2 are significantly higher in 
comparison with the control group, whereas CSF tau protein concentration does not change 
significantly, suggesting that CSF TG2 concentration could be an important  biomarker for this 
neurodegeneration disease
25
. 
3) TG2 colocalizes with amyloid deposits in the brains of AD patients. Several in vitro 
immunochemical studies showed the presence of TG2 in both isolated amyloid plaque cores and 
cortex tissue sections from patients affected by AD. These results provide evidence that insoluble 
amyloid deposits may involve TG-mediated cross-linked Aβ-peptide polymer26.  
4) TG2 activity is increased in AD brain. In a study conducted by Johnson G.V. et al. that used 
frozen prefrontal cortex and cerebellum samples from Alzheimer's disease, a total 
transglutaminase activity significantly higher in the AD prefrontal cortex compared to control was 
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observed. In addition, the levels of TG2, as determined by quantitative immunoblotting, were 
elevated approximately 3-fold in AD brain with respect to control. In contrast, in the cerebellum 
which usually is not impaired in AD, no significant increment in transglutaminase activity or 
levels has been detected
27
. 
5) Catalytically active TG2 colocalizes with Aβ in AD animal models. A recent in vitro study 
investigated the role of TG2 in AD pathology using two mouse models that represent early and 
late stages of pathology development for this purpose. According to the results, the general 
distribution pattern of TG2 in transgenic mice is similar to the observations in human brains. In 
fact, there was association of both TG2 and in situ active TG2 with Aβ plaques and vascular Aβ, 
indicating that alike human AD cases, TG2 was associated with Aβ depositions in the animal 
models. Although spatial overlay of TG2 with Aβ pathology observed in the mouse models was 
substantially different from observations in human samples, this finding provide evidence for a 
role of TG2 in Aβ pathology28.  
In summary, given these evidences on the role of TG2 in the initiation and development of protein 
aggregates in AD, its distribution overlay with the disease hallmarks and its increased activity in the 
same pathology, it is highly suggested the possibility to use inhibitors of the cross-linking activity of 
TG2 as a new therapeutic approach for AD. 
 
 
1.4 Transglutaminase 2 inhibitors 
The range of pathologies in which TG2 is implicated demonstrated the need for potent TG2-specific 
inhibitors. To date, TG2 inhibitors have been generally divided into two classes based on the 
inactivating mechanism of the enzyme: reversible (competitive and non-competitive) and irreversible 
inhibitors.  
 
1.4.1 Irreversible TG2 inhibitors 
Most irreversible TG2 inhibitors are designed to target the active site cysteine (Cys
277
) using 
electrophilic functional groups. These inhibitors prevent enzyme activity by covalently modifying 
the enzyme, thereby preventing substrate binding. 
 
 Halomethyl carbonyl inhibitors 
This class of inhibitors has been developed based on the structure of iodoacetamide, which was one 
of the first irreversible inhibitors and was able to inactivate guinea pig liver TG2
29
. More recently, 
the Keillor group made a series of chloromethyl ketones and combined them with a Cbz-Phe 
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scaffold, where Cbz functional group was previously assessed to be essential for active site 
recognition
30
. The best inhibitor (compound A) showed a Ki = 6μM and a good specificity profile 
with very low reactivity toward glutathione, the most abundant physiological thiol present in living 
cells
31
.  
 
 
 3-Halo-4,5-dihydroisoxazole inhibitors 
Acivicin is a natural product that is known to inhibit several cysteine-dependent enzymes. The 
scaffold 3-halo-4,5-dihydroisoxazole showed to be able to alkylate the active site cysteine of two 
bacterial glutamine amidotransferases
32
. A number of TG2 inhibitors structurally containing the 3-
halo-4,5-dihydroisoxazole warhead have been developed. In particular, Khosla group synthesized a 
large series of 3-bromo analogs where the electrophilic warhead is linked to a Cbz moiety through a 
peptidic spacer. The dihydroisoxazole compounds were assayed against recombinant human TG2 
using an enzyme-coupled assay, where glutamate dehydrogenase was used to couple ammonium ion, 
a product of the TG2-catalyzed reaction. The most potent derivative was compound B, which 
showed high specificity for human TG2 but essentially no reactivity toward physiological thiols, and 
exhibited good oral bioavailability in mice
33
. Importantly, compound B showed excellent synergism 
with antitumor drug carmustine, against refractory glioblastoma in mice, through a mechanism that 
involves disruption of fibronectin assembly in extracellular environment
34
. 
 
 
 α,β-unsaturated amide 
α,β-unsaturated amide, termed “Michael acceptors”, have been used to inhibit many cysteine 
proteases showing good outcome
35
. Keillor and coworkers synthesized novel TG2 irreversible 
inhibitors by attaching an α,β-unsaturated amide to the typical Cbz-Phe scaffold and varying the 
chain length of the spacer. It was noted that a spacer length of four methylene units (compound C) 
provided a potent inhibitor with inhibitory efficiency of 42-fold more efficient than the same Cbz-
Phe scaffold bearing a halo-dihydroisoxazole group
31
. 
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Compound D is identified as a potent TG2 inhibitor during an extensive drug-screening against the 
enzyme conducted by a biomedical foundation for Huntington’s disease. This compound exhibited 
an IC50 of 10nM against recombinant human TG2 and showed an enormously higher selectivity 
against other TG isoforms, such as FXIIIa, TG6, TG1 and TG3
36
. Low plasma stability of compound 
D leaded to the development of two newer compounds (E and F) which demonstrated superior 
plasma stability and resistance to glutathione conjugation
36
. 
 
 
1.4.2 Reversible inhibitors 
The first reversible inhibitors used in TG2 related research were amine-bearing molecules, typically 
characterized by a medium to long saturated aliphatic chain with a terminal amine group. Some of 
the most commonly used competitive amine inhibitors include putrescine, monodansylcadaverine, 5-
biotinamidopentylamine and fluorescein cadaverine
37
. These inhibitors exert their activity by 
competing with the natural amine substrate in the cross-linking reaction. Thus, TG2 is still 
enzymatically active in the presence of competitive amine inhibitors. One compound of this class is 
represented by cystamine, which is a diamine capable of competitive amine inhibition through its 
reduced form, cysteamine
38
. However, lack of selectivity has been observed for cystamine, since it 
inhibits also the thiol-dependent protease caspase 3 and causes increased production of glutathione 
inside of cells
39
. The amine competitive inhibitors were extensive used in the early research studies 
on transglutaminases, although useful for in vitro studies, they have limited applications since the 
resulting aminated protein could elicit autoimmune response in vivo
40
. 
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Recenty developed TG2 reversible inhibitors with competitive inhibition mechanisms include: 1) 
acylideneoxoindoles derivatives, based on the structure of isatin whose analogs are widely used as 
reversible inhibitors of Cys-dependent proteases
41
; 2) 3-alkynyl quinoxaline derivatives identified 
through screening of 1000 small molecules as TG2 inhibitors using a cancer cell proliferation 
inhibition assay
42
. 
 
 
TG2 is allosterically deactivated upon binding of guanine nucleotides, as aforementioned, thus, there 
has been an effort to develop reversible TG2 inhibitors targeting the GDP/GTP pocket on the 
enzyme. Non-hydrolysable GTP analogs, such as GTPγS and GMP-PCP, have been used as 
reversible inhibitors
4
. A new class of allosteric TG2 inhibitors, discovered during high throughput 
screening, is structurally characterized by the thieno[2,3-d]pyrimidin-4-one acylhydrazides 
backbones
43
. In particular, the compound G showed to be a slow-binding inhibitor that likely does 
not bind at the enzyme’s active site but rather at the enzyme’s GTD binding site and that was non-
competitive with the standard acyl-donor and acyl-acceptor substrates
44
. 
 
 
  Trans-cinnamoyl inhibitors of TG2 
One of the most promising TG2 reversible inhibitors recently discovered is represented by the trans-
cinnamoyl derivatives inhibitors. As aforementioned, starting from a comparative study between 
Cbz-Gln-Gly versus Boc-Gln-Gly-binding modes via molecular modeling, the group of Keillor 
discovered the importance of Cbz protecting group to confer active site recognition and improve 
affinity. Further investigation of the rigidity of the Cbz group led to the identification of trans-
cinnamoyl derivatives as competitive and reversible inhibitors with IC50 value for guinea pig liver 
transglutaminase as low as 18µM
45
. The enzyme inhibition assay was performed using the kinetic 
analysis by Michaelis-Menten equation, based on UV-visible detection of a chromogenic TG2 
substrate. According to the structure-activity relationship (SAR) study, the most potent inhibitors are 
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divided into two subclasses, depending on the nature of the heteroaromatic substituent (HET) 
moiety: cinnamoyl benzotriazolyl amide and 3-substituted cinnamoyl pyridines, referred to more 
commonly as azachalcones. Initial SAR investigations on the aromatic scaffold of cinnamoyl moiety 
showed that substituents in para position improved the affinity with enzyme. In particular, 
substituents with a sp2-hybridized oxygen, such as NO2, BOCNH, FmocNH and MeO2C, conferred 
the best inhibitory activity. While the HET moiety seemed involved in hydrogen bond connection 
inside the enzyme, thus, aromatic moiety possessing hydrogen bond acceptor like benzotriazolyl and 
pyridinyl group is mandatory for a good affinity for this series of compounds. Finally, evaluation on 
the importance of the length and flexibility of the linker between the two aromatic moieties showed 
that introduction of a supplementary conjugated alkene was detrimental to the affinity for TG2, in 
comparison with the cinnamic double bond. Moreover, the reduction of the alkene or replacement 
with methylene/ether led to a loss of activity. For the selectivity studies of this new family of TG2 
inhibitors, several representative compounds were tested as inhibitors on Factor XIIIa, a 
transglutaminase isoform, and Caspase 3, a cysteine protease with acyl transfer mechanism similar to 
that of TG2. As results, most of these compounds showed a good selectivity profile, since no 
inhibitory effect was detected on these enzymes even at concentration approaching the limits of their 
solubility. 
 
Figure 3. General structure of cinnamoyl derivatives and their SAR tendencies. 
 
Subsequent labeling experiments with an azachalcone derivative (compound H) were performed to 
determine the binding mode of the cinnamoyl inhibitors
46
. This inhibitor with IC50 = 28μM was 
designed to incorporate the photolabile diazirine moiety. Photoactivation of diazirine generates diazo 
and carbene derivatives that react rapidly to covalently label residues in their proximity. The 
following LC-MS analysis indicated that Cys230 located inside the hydrophobic groove was 
primarily labeled. Modeling simulations suggest that Cys230 is more exposed in the “closed” 
conformation of TG2 rather than the “open” conformation, in agreement with the result of docking 
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studies. These findings suggest the hypothesis that trans-cinnamoyl inhibitors favorably interact with 
the “closed” conformation of TG2. 
 
 
A more recently developed class of 4-nitrocinnamoyl triazoles by Keillor group
47
 highlighted an 
inhibitor (compound I) which exhibited IC50 value of 2.1µM, representing the most potent inhibitor 
of this class and provided a promising scaffold for building novel TG2 inhibitors.  
 
 
 
1.5 Multitarget ligands approach in drug discovery 
Over the last decades, most drug discovery efforts were aimed at single-target compounds. However, 
not all diseases succumb to this “one disease-one target” approach. Disease systems are generally 
characterized by the dysregulation of multiple biological pathways and efforts of integrating the 
complex disease systems to drug discovery process leaded to a new concept, termed 
polypharmacology: the treatment of diseases by modulating multiple targets. Besides the approaches 
of drug cocktail and multicomponent drugs, the more recently consolidated strategy of 
polypharmacology is the development of multitarget ligands (MLs). Multitarget ligands, designated 
firstly by Morphy et al.
48
, are single chemical entities capable of modulating simultaneously multiple 
targets involved in a certain disease. MLs are gaining increasing attention from the drug discovery 
community and a plethora of multitarget ligands have been developed for the treatments of various 
diseases, by offering a number of potential advantages over the drug cocktail or multicomponent 
drugs: 1) less costly and complicate in clinical development because predicting the pharmacokinetics 
of a single compound is much easier than a drug cocktail; 2) improved efficacy due to the synergistic 
effect of simultaneously inhibiting multiple targets; 3) improved safety with reduced risk of drug-
drug interactions; 4) simplified therapeutic regime and improved compliance. 
 
 
 
 16 
 
1.5.1 Rational design of a multitarget ligand 
A general drug design for MLs starts with identification of two pharmacologically relevant targets, A 
and B, located on complementary pathological pathways, followed by verifying the potential 
synergistic effect from hitting the two targets simultaneously. Afterwards, the pharmacophores 
responsible for binding to target A and B must be identified, and finally, the pharmacophores can be 
linked together in one single entity to obtain hybrid, fused or chimeric dual-target ligands.  
 
 
Figure 4. Dual-target ligand design strategy
49
. 
 
However, there are two main challenges correlated to the development of MLs. First, suboptimal 
physicochemical properties are frequently encountered with the MLs. In fact, MLs currently 
developed tend to be larger and more lipophilic than marketed drugs and are also less efficient than a 
broad set of preclinical compounds in terms of their binding energy per unit of molecular weight or 
lipophilicity, with detrimental consequences for oral bioavailability
50
. A recent paper from Hopkins 
et al. showed that there is a reverse correlation between the mean molecular weight of compounds 
and the total number of targets that those compounds were found to show a minimal activity. This 
finding suggests that smaller molecules are more likely to establish interactions with multiple 
biological targets
51
. Secondly, the lead-to-drug optimization is much more complex for multitarget 
compounds: the binding affinity profiles must be balanced with multiple biological targets. 
Therefore, the ratio of activities at the different target must be adjusted to achieve a good 
pharmacological profile for the MLs. 
 
1.5.2. Multitarget ligands for the treatment of Alzheimer’s disease 
As aforementioned, AD pathogenesis involves a complex interplay of genetic and biochemical 
factors and is phenotypically characterized by hallmarks like Aβ peptide accumulation and increased 
phosphorylation of the microtubule-associated tau protein. Multitarget ligands represent a promising 
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approach for the treatment of this multifactorial disease. To date, a number of MLs toward different 
AD’s pathological targets were developed and showed interesting biological profiles. Some potential 
MLs for AD treatment are reported below. 
The dimer bis-(7)-tacrine was one of the first homodimers reported in the literature with increased 
acetylcholinesterase (AChE) affinity, exhibiting a 1000-fold higher inhibitory potency compared to 
tacrine. The inhibitory profile is due to a simultaneous interaction with both active site and peripheral 
site of AChE, furthermore, the compound is capable to inhibit the AChE-induced Aβ aggregation 
with an IC50=41.7μM
52
. Minarini and coworkers proposed modifications on the structure of bis-(7)-
tacrine by replacing the aliphatic linker with cystamine, which has shown important neuroprotective 
properties
53
. The resulting dimer cystamine-tacrine was able to inhibit AChE (IC50=5.04 nM), 
BuChE (IC50=4.23 nM), self-Aβ aggregation (IC50=24.2μM) and AChE-induced Aβ aggregation 
(52.6%), exhibiting additional neuroprotective effect on SH-SYS5 cell line against H2O2-induced 
oxidative injury
54
. 
 
 
 
The current standard of care for AD is a combination of an AChE inhibitor with the non-competitive 
N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine
55
. The reason for this combination 
therapy is that the NMDAR antagonist would stop or delay neurodegeneration, while the AChE 
inhibitor would improve memory and cognition by stimulating the surviving neurons. Simoni et al. 
combined in single new chemical entities the pharmacophoric moieties of memantine and 
galantamine, two marketed drugs for the treatment of AD, with the latter one being an AChE 
inhibitor
56
. The new chimera compounds were initially investigated by docking simulations based on 
the crystallographic structure of AChE complexed with an inhibitor. The derivatives with various 
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spacer lengthes were then tested against AChE and NMDAR. The most potent derivative, endowed 
with a spacer of eight methylene units, showed an IC50 value of 0.52nM against AChE, albeit it 
turned out to be a weak binder toward NMDAR with IC50 in micromolar range. This series of 
compounds has highlighted the inherent difficulty of balancing the affinity profiles against different 
targets, when discovering and developing MLs. Interestingly, these molecules showed to be active 
also toward NMDAR containing the NR2B subunit, a receptor subunit particularly implicated in 
pathological process linked to overexcitation of glutamatergic pathways. Finally, several derivatives 
of this series exhibited a remarkable neuroprotective profile by inhibiting the NMDA-induced 
neurotoxicity.  
 
 
 
Lu and coworkers
57
 have reported some multitarget directed ligands by combining the stilbene 
moiety of resveratrol with clioquinol. Resveratrol, a natural product with a stilbene structure, has 
been shown to function as an anti-AD agent through the inhibition of Aβ aggregation by scavenging 
oxidants and exerting anti-inflammatory activities
58
, while clioquinol is a well-known metal chelator 
which significantly decreased the rate of cognitive decline in moderately severe AD patients in a 
phase II clinical trial
59
. Two derivatives of these fused MLs exhibited significant inhibition of Aβ 
aggregation, metal-chelating ability, disaggregation of Aβ fibrils generated by self- and Cu(II)-
induced Aβ aggregation, antioxidant activity, acceptable MAO-A and MAO-B inhibition, moderate 
AChE inhibition and low neurotoxicity. One derivative of the series was able to cross the blood-brain 
barrier in vitro and did not exhibit acute toxicity in mice at doses up to 2000 mg/kg. 
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2. Dual inhibitors targeting Transglutaminase 2 and Histone Deacetylase 
 
This chapter focuses on the development of inhibitors designed to hit simultaneously two important 
targets implicated in the pathogenesis of Alzheimer’s disease (AD): Transglutaminase 2 (TG2) and 
histone deacetylase (HDAC). The role that TG2 plays in AD pathology has been elucidated in the 
first chapter, while HDAC, a class of enzymes importantly involved in epigenetic modification of 
gene expression by influencing the status of histone acetylation, has been proved to play a key role in 
various diseases of central nervous system (CNS), including the AD. The inhibitors were designed 
following the frame-combination method to achieve a multitarget activity, in particular by 
combination of the trans-cinnamoyl moiety of a potent TG2 inhibitor and the hydroxamic acid 
functionality, an excellent zinc chelating agent demonstrated to be responsible of HDAC’s inhibition. 
The synthesized multitarget ligands have been evaluated for in vitro inhibition activity on hTG2 and 
all compounds of the series showed good inhibition activities towards this AD target, while the 
results on HDACs inhibition will be ready shortly. 
 
 
2.1 Histone acetylation’s role in the pathogenesis of Alzheimer’s disease 
Epigenetic processes include histone modifications (acetylation, phosphorylation, methylation, 
ubiquitination and ADP ribosylation), DNA methylation and gene silencing by non-coding RNAs. 
Histone acetylation and deacetylation regulate gene transcription by altering the chromatin structure 
and the accessibility to transcription factors. Levels of histone acetylation depend on the activities of 
histone acetylases (HATs) and histone deacetylases (HDACs), which add or remove acetyl groups 
from histone proteins, respectively. Although transcriptional regulation is highly complex and 
dynamic, in general an increase in histone acetylation causes remodeling of chromatin from a tightly 
packed configuration to a loosely packed one, which subsequently leads to transcriptional activation; 
conversely, a decrease in histone acetylation generally results in transcriptional silencing. Therefore, 
an upregulation of transcription can be achieved by either stimulating HATs or inhibiting HDACs. 
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Figure 5. Effect of HDAC inhibitors on chromatin remodelling and transcription
60
. 
 
HDACs repress transcription by removing an acetyl group from lysine residues on histone tails and 
thus compacting chromatin. In addition, a number of non-histone cellular proteins are substrates for 
HDACs, which mediate diverse biological functions via transcriptional-dependent as well as 
independent mechanisms.  
Mammalian HDAC enzymes are classified into four major classes: (1) Class I HDACs contain 
ubiquitously expressed HDACs 1, 2 and 3, and the muscle-specific HDAC8; (2) Class II HDACs 
further separated into two subclasses: class IIa including HDACs 4, 5, 7 and 9 which show distinct 
tissue-specific patterns of expression, predominantly in muscle and heart; class IIb includes the 
unusual HDAC6, which deacetylates α-tubulins and alters microtubule stability, and HDAC10 not 
yet well characterized; (3) Class III HDACs are named sirtuins and includes SirT1-7, sharing their 
homology sequence to the yeast Sir2; (4) The class IV enzyme HDAC11 is structurally different 
from the class deacetylases I and II, and its function is poorly known. Class I, II, and IV HDACs are 
Zn
2+
-dependent enzymes, while Class III HDACs enzymes are dependent on nicotinamide adenine 
dinucleotide (NAD
+
) to carry out their catalytic functions. 
The superfamily of HDACs has been recognized as an important therapeutic target for a broad range 
of human diseases, particularly for cancer treatment. More recently, increasing studies point out 
another important application of HDAC-based therapeutics: as potential treatment for human CNS 
disorders. Genetic evidences suggest crucial roles for HDACs and HATs in the maintenance of CNS 
homeostasis and a possible correlation between mutations in gene encoding histone-binding proteins 
and neurological disorders. In fact, HDAC inhibitors showed interesting results in several in vitro 
studies for the investigation of their potential therapeutic effects in CNS diseases, such as psychiatric 
disorders, Rubinstein-Taybi syndrome, motor-neuron disease and Huntington’s disease60. In 
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particular, HDACs have been correlated directly to AD in several studies. The isoform HDAC2 is 
widely expressed in CNS and negatively regulates memory and synaptic plasticity, it is 
overexpressed in the post-mortem brain samples of AD patients and its knockdown by shRNA 
restores the synaptic plasticity and decreases memory impairments in AD model mice
61
. These 
findings highlight the important role of HDAC2-regulated chromatin modification in regulating the 
synaptic plasticity and memory formation in the cognitive impairment context of AD. Furthermore, 
an increased HDAC6 protein level is observed in the cortices and hippocampus of AD postmortem 
brain samples
62
 and reducing endogenous HDAC6 results in the restore of learning and memory 
deficits in AD mouse model
63
. The mechanism is likely correlated with the involvement of HDAC6 
in tau metabolism, in fact, the selective inhibitor of HDAC6, tubacin, represses tau 
phosphorylation
62
. This enzymatic isoform has been observed to act as regulatory protein of the 
ubiquitin-proteasome system as well, thus, is intimately linked to the aggregation of misfolded 
mutant proteins which represents a hallmark of many neurological disorders
64
.  
HDAC inhibitors exhibited neuroprotective, neurotrophic and anti-inflammatory properties, and 
improve neurological performance -learning and memory- in neurodegenerative disease models. 
Particularly, studies demonstrated that treatment with HDAC inhibitors could affect the AD 
pathology: 1) Sung et al. demonstrated that a mercaptoacetamide-based class II HDAC inhibitor and 
a hydroxamide-based class I and II inhibitor can reduce Aβ levels65; 2) In an AD mice, daily 
injections of 4-phenylbutyrate reversed spatial memory deficits by normalizing tau 
hyperphosphorylation in the hippocampus without affecting Aβ levels66; 3) As aforementioned, 
HDAC6 inhibition by tubacin reduces the protein tau phosphorylation. 
 
 
2.2 HDAC inhibitors 
Trichostatin A (TSA) is the first natural hydroxamate discovered to inhibit HDACs. The crystal 
structure of this inhibitor complexed with a bacterial HDAC-like protein (HDLP) illustrated the 
chemical structural features of the HDAC catalytic core, as well as the configuration of interaction 
inhibitor-enzyme. According to the revealed structure, the active site of HDAC consists of a tubular 
pocket, a zinc-binding site and two Asp-His charge-relay system. TSA binds the enzyme by inserting 
its long aliphatic chain into the HDLP pocket making multiple contacts to the tube-like hydrophobic 
portion of the pocket. The hydroxamic acid group coordinates the zinc in a bidentate fashion 
resulting in a penta-coordinated Zn
2+
, while the aromatic dimetylamino-phenyl group of the TSA 
chain makes contacts at the pocket entrance capping the pocket
67
. The human HDACs crystal 
 23 
 
structures has been revealed later and its structural analysis showed the common active site features 
in agreement with the ones observed in bacterial HDLP.  
 
 
Figure 6. Representation of TSA in the active-site of HDLP
67
. 
 
Generally, the pharmacophore of HDAC inhibitors is composed of three regions: a ‘cap’ region or 
‘surface recognition domain’, which occludes the entrance of the active site pocket; a ‘zinc-binding 
group’ which chelates the zinc ion in the active site and is required for catalytic function; and a 
‘linker’ region, which connects the two moieties. 
 
 
Figure 7. TSA and general structural illustration of HDAC inhibitors. 
 
HDAC inhibitors can be divided into several classes based on the chemical structures: hydroxamates, 
benzamides, aliphatic acids and cyclic peptides.  
- Hydroxamates. The most important compounds of this class are represented by TSA and SAHA, 
structurally characterized by the presence of a hydroxamic acid function, which is an optimal 
chelating agent for Zn
2+
 present in the catalytic active site of HDACs. SAHA, or vorinostat, is a 
pan-inhibitor of class I, II and IV HDACs and demonstrated activity in low nanomolar range
68
. 
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It is the first HDAC inhibitor to be approved for anticancer treatment by FDA. Following 
SAHA, many structural analogs have been synthesized, such as Belinostat and Panobinostat. 
- Benzamides. This class includes two derivatives, Mocetinostat and Etinostat (MS275), both 
achieved in clinical trials. The former one is a class I and IV HDACs inhibitor, while the latter is 
a selective inhibitor for class I. 
- Aliphatic acids. Valproic acid and phenylbutyrate belong to this class and are relatively weak 
inhibitors of the HDACs with activity in millimolar range.  
- Cyclic peptides. The only member of this class is represented by Romidepsin, a natural product 
which showed to be active at nanomolar concentrations, and was approved as anticancer agent. 
 
 
Figure 8.  FDA approved HDACs inhibitors. 
 
An important drawback of most HDAC inhibitors is the lack of isoform-selectivity, which makes it 
difficult to determine whether the biological outcome is due to inhibition of a specific HDAC or by 
inhibition on multiprotein complexes, besides the undesirable clinical effects due to off-target 
activity. Hence, new trend in the field of HDAC inhibitor drug discovery is the development of 
isoform-specific HDAC inhibitors, and to date, a handful of these selective inhibitors has emerged. 
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Table 1. Isoform-specific HDAC inhibitors. 
 
 
 
2.3 Drug design 
AD pathogenesis involves a complex interplay of genetic and biochemical factors and a therapy 
aimed at hitting diverse pathological pathways is strongly recommended. Given the evidences that 
both transglutaminase 2 and HDACs play important role in the pathology of AD and both 
overexpressed in this neurodegenerative disease, inhibition of  these two enzymes could produce 
additive or synergic amelioration of the pathology. This hypothesis is supported by a study 
(unpublished results) which demonstrated that treatment with Vorinostat and cystamine on neuronal 
cells results in a synergic neuroprotective effect against excitotoxicity induced by glutamate; 
additionally, according to a study on Huntington’s disease (HD), combinatorial treatment of SAHA, 
cystamine and Congo red improved survival of Drosophila HD model
69
. Therefore, the aim is to 
apply the ‘multitarget ligands’ approach to develop an inhibitor active on both two biological targets, 
through combination of pharmacologically important fragments for each target to give a single 
chemical entity. 
To the purpose of designing a TG2-HDAC dual inhibitor, we selected a potent TG2 inhibitor bearing 
the trans-cinnamoyl structure, the compound 1, which was found to be a reversible competitive 
inhibitor with IC50=28μM. According to the structure-activity relationship studies, the large 
substituents on the cinnamoyl aromatic ring in the para position gave the best results
46
. Thus, by 
replacing this substituent on compound 1 with an aliphatic chain bearing hydroxamic acid, the zinc 
 26 
 
chelating group responsible of HDACs inhibition exhibited by Vorinostat, we designed a series of 
new compounds 2-4 where the two fragments are connected through a linker. 
 
Figure 9. Drug design of compounds 2-4. 
 
The conjugates 2-4 are structural analogs with difference in the linker length, which is composed of 
2, 4 and 5 methylene units, respectively, along with a thiourea bond, chosen for the reason of 
synthetic accessibility. The derivative characterized by three methylene units as linker was designed 
as well, but the chemical synthesis could not be accomplished despite numerous synthetic attempts. 
We postulated that these new chemical conjugates would maintain inhibition activity on HDACs and 
TG2 by the reason of the presence of both pharmacophores; additionally, we assume that the bulky 
trans-cinnamoyl moiety would serve as ‘surface recognition group’ for HDACs, allowing favorable 
orientation of hydroxamic acid inside the active site pocket.  
 
 
2.4 Methods 
Compounds 2-4 were synthesized and studied in in vitro inhibition assays on TG2, while the 
inhibition activities on HDACs are still under investigation. According to the preliminary data, the 
compounds showed good inhibition activities on TG2 in an assay conducted on human recombinant 
transglutaminase 2 using a chromogenic donor substrate.  
 
2.4.1 Synthetic methods 
The compounds 2-4 were synthesized following the scheme 1: The trans-cinnamoyl moiety was 
synthesized starting from an aldol condensation reaction between 3-acetylpyridine and para-nitro 
substituted benzaldehyde in basic conditions to give compound 5, followed by reduction of nitro 
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group into the correspondent amine using Tin(II) chloride to afford compound 6. The amine group 
was then transformed into isothiocyanate (compound 7) by reacting with 1,1′-Thiocarbonyldi-2(1H)-
pyridone. 
For the synthesis of the aliphatic chain bearing hydroxamic acid, commercially available bromo-
alkyl carboxylic acids were subjected to nucleophilic substitution to replace the halogen with azide 
group by reacting with sodium azide to give compounds 8-10. Afterwards, the carboxylic acid was 
reacted with O-Tritylhydroxylamine in a coupling reaction to give the correspondent protected 
hydroxamic acids 11-13. The azide group was then converted to amine through Staudinger reaction 
using triphenylphosphine.  
The two moieties were finally linked together in a coupling reaction where the electrophilic carbon 
of isothiocyanate reacts with the nucleophilic amine to form a thiourea bridge connecting the two 
fragments. 
Finally, the trityl group of hydroxamic acid was cleaved in acidic conditions in the presence of 
triethylsilane as scavenger to afford the final products 2-4. The derivative characterized by a linker of 
three methylene units was not obtained despite numerous synthetic attempts. 
 
 28 
 
 
Scheme1. a) KOH, MeOH/H2O, 30min, r.t.; b) SnCl2, EtOH, 30min, 70°C; c) 1,1′-Thiocarbonyldi-2(1H)-pyridone, 
DCM, overnight, r.t.; d) NaN3, DMF, 5h, reflux; e) O-Tritylhydroxylamine, IBCF, NMM, THF, 2h, r.t.; f) PPh3, DCM, 
overnight, r.t.; g) DCM, overnight, r.t.; h) TFA, Et3SiH, r.t., 30 min. 
 
2.4.2 In vitro TG2 inhibition assay 
According to a study conducted by Keillor group, TG2 reacts with N-Cbz-Glu(γ-p-
nitrophenylester)Gly, a TG2 acyl-donor substrate analog, to undergo rapid acylation that can be 
followed spectrophotometrically at 400nm. The inhibition activity of the synthesized compounds 2-4 
was evaluated using this method on human recombinant TG2. The IC50 values were determined 
based on the inhibition of the enzymatic reaction of 2.2mM of N-Cbz-L-Glu(γ-p-
nitrophenylester)Gly with 0.5mU of human recombinant TG2. 
Briefly, kinetic runs were recorded at 25°C on a UV-visible spectrophotometer at 405nm, in a buffer 
composed of 3-(N-morpholino)propanesulfonic acid (MOPS, pH = 7.0), CaCl2 and EDTA. Each 
kinetic assay was performed using 180μL buffer, 5μL of a DMSO stock solution of substrate N-Cbz-
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Glu(γ-p-nitrophenylester)Gly, 10μL of a solution of hTG2 and 0 to 5μL of a DMSO stock solution of 
inhibitor. IC50 values were obtained as the negative x-intercept of a Dixon plot. 
 
 
2.5 Results and discussions 
The test compounds were subject to preliminary studies for in vitro evaluation of the inhibition 
activity on hTG2 enzymatic function and the IC50 values are reported in Table 2.  
From an analysis of the results, the compound 3 exhibited the best activity with IC50=13μM. Among 
the class of trans-cinnamoyl inhibitors, endowed with a competitive reversible mechanism of 
inhibition, the IC50 for the most potent inhibitor was determined to be 2.1μM. This inhibitor belongs 
to the subclass of cinnamoyl-triazoles (see chapter 1); while the best inhibitor of the subclass of 
cinnamoyl-pyridine showed an IC50 value of 21μM, as reported in literature. All three synthesized 
derivatives 2-4 of the series are characterized by cinnamoyl-pyridine structure, and showed a good 
TG2 inhibition activity. In particular, the compound 3 could be considered the most potent 
cinnamoyl-pyridine inhibitor reported so far in literature. 
The structural difference within this series of compounds resides in the chain length of the linker. An 
observation on inhibition potency of these compounds could drive to the conclusion that the presence 
of a bulky moiety in para position on the aromatic ring is not harmful in terms of inhibition activity, 
in agreement with observations reported in literature. Furthermore, the results show that the chain 
length can affect the inhibitor’s activity and the derivative with four methylene units probably fits 
better than other analogs in the active site of the TG2 enzyme. 
 
Table 2. IC50 values of the TG2 inhibitors 2-4. 
Compound Structure IC50 (μM) 
2 
 
24.3 ± 1.2 
3 
 
13.3 ± 1.5 
4 
 
22.1 ± 2.0 
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2.6 Conclusions 
The series of derivatives 2-4 were designed to be dual inhibitors targeting simultaneously HDACs 
and TG2, by incorporating the trans-cinnamoyl fragment for TG2 inhibition and hydroxamic acid 
moiety for the inhibition of HDACs.  
At the time of edition for the present manuscript, we cannot elaborate final conclusions. However, 
preliminary in vitro data showed that the compounds of this series are good TG2 inhibitors. The best 
inhibitor was compound 3, which exhibited an IC50 value of 13µM and could be the most potent 
inhibitor within the subclass of trans-cinnamoyl pyridines currently developed and reported. The 
mode of inhibition of these compounds is currently under investigation; while studies on the 
inhibition activity on HDACs are in progress. 
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3. Trans-cinnamoyl structure based transglutaminase 2 inhibitors with 
potential antioxidant activities 
 
Oxidative stress is one of the key factors in the AD’s pathology, and among various cell damage 
mechanisms, it promotes Aβ toxicity and increases tau hyperphosphorylation where the enzyme 
GSK3β could be involved in the pathological mechanisms. Natural antioxidants like 
hydroxycinnamic acids, including caffeic acid, ferulic acid etc., exert neuroprotective activities 
against neuronal cell damage induced by oxidative stress. Based on the trans-cinnamoyl structure 
which is essential for TG2 inhibition, addition of hydroxyl groups on the aromatic ring allowed the 
obtainment of a series of compounds designed as‘fused’multitarget ligands, which could be TG2 
inhibitors and at the same time antioxidant agents. In vitro antioxidant evaluation outlined one 
compound of the series as a good antioxidant and endowed with interesting biological activity 
toward Aβ self-aggregation process and GSK3β enzyme activity. Against expectation, the slight 
structural modifications determined an almost complete loss of inhibition toward TG2. 
 
 
3.1 Oxidative stress in Alzheimer’s disease 
Oxidative stress is a mechanism of cell damage characterized by excessive production of highly 
reactive free radicals. It is the result of an imbalance in pro-oxidant/antioxidant homeostasis, which 
leads to the generation of toxic reactive oxygen species (ROS). The instability of free radicals is due 
to the presence of an unpaired electron on the outer orbital. This is responsible for the high reactivity 
of these species. ROS can potentially react with many cellular components including lipids, proteins 
and DNA, resulting in impaired cellular functions and formation of toxic species, such as peroxides, 
aldehydes and cholesterol oxide. 
Unsaturated lipids are particularly susceptible to oxidative modification and lipid peroxidation is a 
sensitive marker of oxidative stress. Lipid peroxidation, which is the result of the attack by radicals 
on the double bond of unsaturated fatty acids, generates lipid peroxy radicals which initiates a chain 
reaction and breakdown products such as 4-hydroxy-2,3-nonenal (HNE), acrolein and 
malondialhedyde, molecules highly toxic for cells and all increased in neurodegenerative models
70
. 
The excessive production of ROS leads to disregulation of intracellular calcium signaling and such 
disregulation has been widely observed in neurodegenerative diseases
71
. One of the downstream 
events that occurs in response to an ROS-induced calcium influx is an excitotoxic response
72
, that is 
activation of glutamate receptors that triggers a cascade of events leading to cell death. Excitotoxic 
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response has been implicated in several neurological conditions as well as neurodegenerative 
diseases such as AD, Parkinson Disease (PD) and Huntington’s disease73. 
The neurons are particularly susceptible to oxidative stress for several reasons. The first one is that 
the membrane of neuron cells contains elevated amount of unsaturated fatty acids, which are 
excellent substrate for the lipid peroxidation chain reactions; the second one, is that neuronal 
functions require a large amount of energy generated through oxidative phosphorylation reactions; 
the third one, is that the brain is an organ that concentrates metal ions, such as copper and iron. 
Therefore, the vulnerability of neuron cells to the oxidative stress is strongly related to the 
pathogenesis of neurodegenerative diseases.  
 
3.1.1 Metal ions and Aβ toxicity 
The hypothesis that oxidative stress could be an important factor to AD’s pathogenesis and 
progression is widely accepted. A support to this hypothesis is the correlation found to exist between 
metal ions and amyloid-β peptide (Aβ).  
As a general principle, the chemical origin of the majority of ROS is the reaction of molecular 
oxygen with the redox-active metals, copper and iron. The ability of these metal ions of initiating 
redox cycling and activating molecular oxygen is the basis of function for most of enzymes.  
Aβ is the major component of amyloid plaques and studies showed that there were remarkably high 
concentrations of Cu, Zn and Fe in the amyloid deposit in AD-affected brains
74
. The cause of the 
neuronal cell loss in AD might be related to oxidative stress from excessive free-radical generation 
and the major source of oxidative stress in the brain of AD is likely the transition metals Cu and Fe 
when bound to Aβ75. According to a study by Opazo et al., when Cu2+ or Fe3+ coordinate Aβ, 
extensive redox chemical reactions take place that reduce the oxidation state of both metals and 
produce H2O2 from O2 in a catalytic manner
76
. The formal reduction potential of Cu
2+
 to Cu
+
 by Aβ42 
is highly positive and typical of strongly reducing cupro-proteins. The toxicity of Aβ against 
neuronal cells is enhanced by the presence of Cu, which is usually present in culture media. Aβ 
possesses histidine residues at positions 6, 13 and 14 forming a structural element that enable Aβ to 
coordinate transition metal ions
77
; in fact, studies confirmed that histidine is the principal site of 
metal coordination. 
 
3.1.2 Tau hyperphosphorylation and oxidative stress 
Tau hyperphosphorylation appears to be a critical event leading to abnormal aggregation and 
disrupted function of tau in affected AD neurons. As a prominent early event during AD 
 33 
 
pathogenesis, oxidative stress is believed to have important connections with tau phosphorylation 
and the formation of neurofibrillary lesions.  
Several studies performed on cellular or animal models of tau pathology have established that 
overexpression of mutant forms of human tau increases both expression of oxidative markers and the 
sensitivity of neurons to oxidative molecules. In fact, following overexpression of wild-type tau in a 
neuroblastoma cell line, an increased susceptibility to H2O2 was observed
78
. Furthermore, using 
transgenic mice carrying human tau
P301L
 protein, biochemical analysis showed an increased ROS 
production and lipid peroxidation in the brain, elevated activities of antioxidant enzymes and 
evidence of mitochondrial dysfunction
79
. In another mice model expressing human tau
P301S
 protein, 
tau hyperphosphorylation and tangle formation were detected and associated with GSK3β activation. 
In these mice, also elevated protein carbonyl levels, an indicator of protein oxidation, were detected 
in the brain
80
. These studies establish that expression of tau mutants in animal models induces 
oxidative stress in neurons.  
From the other hand, there are evidences suggesting that accumulation of ROS can directly stimulate 
tau hyperphosphorylation and aggregation. 4-hydroxy-2-nonenal (HNE), a product of lipid 
peroxidation, facilitates aggregation of phosphorylated tau in vitro
81
 and induces tau 
hyperphosphorylation
82
. Also oxidized fatty acids have been shown to stimulate tau polymerization 
in vitro
83
. However, the mechanism by which oxidative stress affects tau phosphorylation remains in 
discussion. GSK3β, a serine/threonine kinase, is involved in tau hyperphosphorylation. Lovell et al. 
reported that the treatment of primary rat cortical neuron cultures with a combination of cuprizone, a 
copper chelator, Fe
2+
 and H2O2 significantly increased GSK3β activity and pathologic tau 
hyperphosphorylation. Treatment of the same cultures with LiCl, an inhibitor of GSK3β, remarkably 
decreased abnormal tau phosphorylation, suggesting that GSK3β could be the enzyme involved in 
tau hyperphosphorylation in oxidative conditions
84
. Moreover, treatment of neuronal cells exposed to 
H2O2 with GSK3β inhibitors protected the cells against oxidative stress. By contrast, higher 
concentrations of the same inhibitors induce opposite effects
85
.  
These studies suggest that GSK3β plays important roles in tau pathologies and mild inhibition of its 
activity may prevent tau phosphorylation induced by oxidative stress. 
 
3.2 Cinnamic acid derivatives as antioxidants 
Polyphenols are naturally occurring compounds found largely in the fruits, vegetables, cereals and 
beverages. They are secondary metabolites of plants and are generally involved in defense against 
ultraviolet radiation or aggression by pathogens. They consist of a large variety of molecules, but 
most of these compounds arise from a common structural origin: the amino acids phenylalanine or 
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tyrosine. Biosynthesis through the phenylpropanoid pathway produces the large variety of the plant 
polyphenols, including cinnamic acids, benzoic acids, flavonoids, proanthocyanidins, coumarins, 
stilbenes and lignans.  
Dietary polyphenols are thought to be beneficial for human health by exerting various biological 
effects, such as free-radical scavenging, metal chelating, modulation of enzymatic activity and 
alteration of signal transduction pathways
86
. Epidemiological studies have shown some relationships 
between consumption of polyphenol-rich foods and prevention of diseases, such as cancer, coronary 
heart disease, diabetes and neurodegenerative diseases
87
. 
 
3.2.1 General antioxidant mechanisms of polyphenols 
In the last decade, polyphenols are subject of increasing scientific interest because of their beneficial 
effects on human health. Their antioxidant properties are the most widely investigated therapeutic 
activity 
88,87
. 
The chemical structure of polyphenols confers them the ability to act as free radical scavengers. In 
fact, phenolic hydroxyl groups are good hydrogen donors, thus, can react with reactive oxygen and 
reactive nitrogen species
89
 in a termination reaction, which breaks the cycle of generation of new 
radicals. Following interaction with the initial reactive species, a radical form of the antioxidant- 
phenoxyl radical is produced, having a much greater chemical stability than the initial radical. The 
interaction of the hydroxyl groups of phenolics with the π-electrons of the benzene ring allows the 
free radical to be stabilized by delocalization.  
The antioxidant capacity of phenolic compounds is also attributed to their ability to chelate metal 
ions
90
, such as iron, a redox-active metal that catalyzes free radicals formation. Other authors refer to 
the inhibition of oxidases, such as lipoxygenase (LO), cyclooxygenase (CO), myeloperoxidase 
(MPO), NADPH oxidase and xanthine oxidase (XO)
91
, as important mechanisms for avoiding the 
generation of higher amounts of ROS in vivo, as well as organic hydroperoxides. 
On the other hand, to date, a number of polyphenols, such as quercetin, myricetin, kaempferol and 
caffeic, chlorogenic and ferulic acids, have been reported to possess also pro-oxidant activity
92
. 
However, it is recognized that the pro-oxidant activity of natural polyphenols has a more specific 
preference against certain cellular targets and appears to play a role in the prevention of certain types 
of cancer
93
. 
 
3.2.2  Classes of polyphenols 
Polyphenols can be sub-classified into four main groups: flavonoids, phenolic acids, stilbenes and 
lignans. 
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Flavonoids comprise the most studied group of polyphenols. This group has a common basic 
structure consisting of two aromatic rings (ring A and ring B) bound together through a three carbon 
chain that form a closed pyran ring (ring C). More than 4000 varieties of flavonoids have been 
identified, many of which are responsible for the attractive colors of the flowers, fruits and leaves 
and constitute a protection from UV radiation. Based on the variation in the type of heterocycle 
involved, flavonoids may be divided into six subclasses: flavonols, flavones, flavonones, flavanols, 
anthocyanins and isoflavones. Flavonoids became the subject of medical research and have been 
reported to possess many beneficial properties, including antioxidant, anti-inflammatory, 
antimicrobial, antiviral, antiallergic, anticancer activity
94
. 
 
 
Figure10.  Chemical structures of different classes of polyphenols. 
 
Stilbenes contain two phenol moieties connected by an ethene bridge. Occurrence of stilbenes in the 
human diet is quite low. Most stilbenes in plants act as antifungal response to infection or injury. 
One of the best studied naturally occurring polyphenol stilbene is resveratrol, found largely in grapes 
and extensively studied for its antioxidant activity
95
. While lignans are diphenolic compounds that 
contain a 2,3-dibenzylbutane structure that is formed by the dimerization of two cinnamic acids 
residues, and linseed represent the richest dietary source. Several lignans are considered to be 
phytoestrogens. 
The class of phenolic acids are found abundantly in foods, and divided into two subclasses: benzoic 
acid derivatives and cinnamic acid derivatives. The hydroxybenzoic acids have generally low 
concentration in plants with exception of certain red fruits, black radish and onions
96
. The cinnamic 
acid derivatives are presently more abundantly in plants and generally are more efficient as 
antioxidant in comparison with their benzoic counterparts. They are biosynthesized from L-
phenylalanine via deamination by phenylalanine ammonia-lyase (PAL). Among the most well-
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known hydroxycinnamic acids, there are caffeic acid, ferulic acid, chlorogenic acid and p-coumaric 
acid, as well as some esterified forms such as caffeic acid phenethyl ester and ferulic acid phenethyl 
ester.  
 
3.2.3 Antioxidant activity of hydroxycinnamic acids 
Over the past decades, the antioxidant property of hydroxycinnamic acids was extensively 
investigated and some structure-activity relationships were already published.  
Caffeic acid is the most predominant phenolic acid in sunflower seeds and it demonstrated high 
inhibition efficiency on lipid oxidation in studies that investigated the antioxidant and free radical 
scavenging properties of six natural hydroxycinnamic acid compounds using three different 
evaluation models: Rancimat method, 1,1-diphenyl-2picryhydrazyl (DPPH) scavenging model and 
oil-in-water emulsion system
97
. Some researchers reported that the thermal decomposition products 
of caffeic acid showed antioxidative activity stronger than caffeic acid itself
98
.  
Chlorogenic acid is an ester formed between caffeic acid and quinic acid. It is widespread in plants 
and the level in coffee beans is elevated constituting up to 10% of the weight. Although chlorogenic 
acid is considered as an antioxidant, it demonstrated less activity than its metabolite, caffeic acid
97
. 
The uptake of chlorogenic acid by mucosal cells is much less than that of caffeic acid and the 
protective effect by the two compounds is almost the same. This finding suggests that the antioxidant 
activity of chlorogenic acid derives from the fraction of caffeic acid hydrolyzed in intestine as 
reported in a study on protective effect of chlorogenic acid and caffeic acid against 
ischemia/reperfusion injury carried out in the rat small intestine
99
.  
Ferulic acid occurs widely in grain foods and vegetables. Phenethyl esters of caffeic acid and ferulic 
acid are the major components in honeybee propolis, a folk medicine used as anti-inflammatory 
agent for centuries. Ferulic acid showed a lower antioxidant activity in comparison with other 
hydroxycinnamic acids, like caffeic and sinapic acid. Additionally, alkyl ferulates showed the same 
activity against DPPH radical but their activity was lower in comparison with ferulic acid. Whereas 
in other methods using ethanol-buffer system and liposome system, esters of ferulic acid resulted 
more active than ferulic acid
100
.  
p-Coumaric acid is another hydroxicinnamic derivative which demonstrated to be capable of 
scavenging OH  radicals and reducing low-density lipoprotein (LDL) peroxidation, according to a 
study on the antioxidant mechanisms of this compound
101
. This study investigated whether p-
coumaric acid (CA) could act as a direct scavenger of reactive oxygen species and whether it could 
minimize the oxidation of LDL. In vitro electron spin studies were conducted to determine the ability 
for CA of scavenging ROS and altering LDL oxidation. CA effectively scavenged OH in a dose-
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dependent manner with IC50 for ·OH scavenging of 4.72 mM. CA was administered to rats and levels 
of 8-epiprostaglandin F2a were monitored as a LDL oxidation marker. The results showed that oral 
administration for 30 days significantly inhibited LDL oxidation.  
According to SAR studies, with regard to the aromatic substitution, the order of effectiveness of 
antioxidant activity within the class of hydroxicinnamic acids was: p-hydroxydimethoxy> 
dihydroxy> p-hydroxy methoxy> p-hydroxy. The increase of methoxy groups or the catechol 
structure substantially increased the antioxidant activity of the compounds by further stabilizing the 
phenoxyl radical. The antioxidant capacity of phenols is ascribed to the formation of resonance-
stabilized phenoxyl radicals after reacting with oxidants
102
. This activity is strengthened by the 
presence of a second hydroxyl group, as in caffeic acid, by virtue of the formation of an 
intramolecular hydrogen bond. Moreover, in the case of Cu(II)-catalyzed oxidation, only the 
presence of two hydroxyl groups in ortho position can allow the formation of Cu(II)-phenolic acid 
complex, resulting in a chelating effect towards the metal
103
. 
 
 
Figure11. General structure-activity relationships for hydroxycinnamic acids. 
 
Most of the hydroxycinnamic acids exhibit neuroprotection activities. Ferulic acid provided 
neuroprotection against oxidative stress-related apoptosis following cerebral ischemia/reperfusion 
injury in rats
104
; also, it showed to regulate positively the expression level of γ-enolase, a neuron-
specific enolase with neuroprotective effect, in brain injury and glutamate exposure-induced 
neuronal cell death
105
. Caffeic acid was demonstrated to exert protective effect against hydrogen 
peroxide-induced oxidative damage on brain tissue
106
. 
 
 
3.3 Drug design   
Oxidative stress is a one of the key factors in the AD’s onset and progression and as explained in this 
chapter, it is correlated to Aβ and protein tau pathways, since it promotes Aβ toxicity and vice versa, 
and increases tau hyperphosphorylation, probably through a mechanism of enhancing GSK3β 
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activity. Hydroxycinnamic acids are a class of phenolic acids with assessed antioxidant activity 
exerting neuroprotective activities against neuronal cell damage induced by oxidative stress. On the 
other hand, trans-cinnamoyl derivatives showed important inhibition activity towards 
transglutaminase 2, an enzyme significantly involved in AD pathogenesis, and whose expression is 
significantly increased in brain areas affected by AD, as described in the chapter 1. Therefore, the 
aim of constructing a multitarget ligand in this context can be realized by designing a chemical entity 
that could be a good TG2 inhibitor and at the same time endowed with antioxidant activity. 
Comparison between hydroxycinnamic acids and trans-cinnamoyl derivatives highlights a clear 
structural similarity- the cinnamoyl backbone; this means that it would be convenient to build a 
‘fused’ multitarget ligand, where the identical fragment from two molecules is overlapped into a 
single molecule.  
Based on the SAR studies, for TG2 inhibition, the pyridine moiety and cinnamoyl backbone are 
essential for the biological activity, with pyridine replaceable by a heterocyclic ring capable of 
hydrogen bond formation. While substituents on the benzene ring should contain a sp2-hybridized 
oxygen, such as NO2, BOCNH, FmocNH and MeO2C, with para position conferring the best 
activity. Concerning the hydroxycinnamic acids, the level of the antioxidant activity depends on the 
presence of OH groups in ortho position and methoxy groups, whereas esterification of the acid 
group confers, in some cases, a more potent antioxidant activity, suggesting that structural 
modification in this portion is feasible and not harmful in term of activity. Therefore, by overlapping 
the cinnamoyl backbone, we designed a series of derivatives 20-24 as potential trans-cinnamoyl TG2 
inhibitors bearing antioxidant activity.  
 
Figure12. Drug design of compounds 20-24.  
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In particular, compounds 20 and 21 are analogs to ferulic acid where 21 presents an ethoxy group 
instead of methoxy. By replacing the aromatic ring with catechol moiety of caffeic acid, compound 
22 was designed. Compound 23 derives from p-coumaric acid, whereas compound 24 is an analog 
with hydroxyl group in meta position on the benzene ring.  
By designing this series of compounds, we postulate that since the trans-cinnamoyl structure and 
pyridine are unmodified, the inhibition activity on TG2 would be preserved, while inserting hydroxyl 
groups on benzene ring we would obtained a phenol/catechol fragment, which would additionally 
confer an antioxidant property to these molecules, as observed for the hydroxycinnamic acids. 
 
 
3.4 Methods 
The series of compounds 20-24 have been synthesized and were primarily subject to evaluation for 
their antioxidant activity using a method based on autoxidation measurement.  The inhibition activity 
on TG2 was determined using chromogenic substrate, as reported in chapter 2. Additionally, the 
compounds were investigated for their potential inhibition effects on Aβ self-aggregation process and 
on GSK3β enzyme activity. These two targets are strictly related to the formation of senile plaque 
and neutrofibrillary tangles, respectively, which represents two main hallmarks in AD pathology.  
 
3.4.1 Chemical synthesis 
The compounds 20-24 were synthesized following the procedure reported in Scheme 2. Briefly, the 
phenolic groups of the appropriate aldehyde were protected as tetrahydropyranyl ethers by reacting 
with 3,4-dihydro-2H-pyran in the presence of pyridinium-p-toluenesulfonate as catalyst. This last 
reagent was synthesized by reacting p-toluenesulfonic acid with pyridine. The resulting derivatives 
25-29 were subject to aldol condensation reaction with 3-acetylpyridine in basic conditions to give 
the derivatives 30-34. Tetrahydropyranyl protecting groups were cleaved using p-toluenesulfonic 
acid in methanol affording the final products 20-24 as phenolic analogs. 
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3.4.2 Evaluation of antioxidant activity and in vitro TG2 inhibition assay  
The compounds were firstly tested to assess the antioxidant property in vitro. To this aim,  the 
method of measurement is based on the comparison between the extent of the autoxidation of the 
substrate both in the presence and in the absence of antioxidants. In particular, the autoxidation level 
was measured through determination of oxygen consumption in a closed system. In a typical 
experiment, cumene is used as oxidazable substrate and 2,2’-azobis-isobutyronitrile (AIBN) as 
oxidation initiator: a solution of cumene in clorobenzene (PhCl) containing AIBN was equilibrated at 
30°C with an identical reference solution. After equilibration and when a constant O2 consumption 
was reached, a concentrated solution of the antioxidant was injected in the sample flask. The oxygen 
consumption in the sample was measured after calibration of the apparatus. The inhibition rate 
constants Kinh were determined by using the kinetic equations.  
The in vitro inhibition assay on TG2 was performed following the method reported in chapter 2. 
 
3.4.3 In vitro evaluation of inhibition on Aβ self-induced aggregation and GSK3β activity 
The inhibitory potency of compounds 20-24 on amyloid fibrils formation was determined using 
Thioflavin T (ThT) fluorescence assay. ThT is a fluorescent dye widely used for the identification 
and quantification of amyloid fibrils because of its strong interaction with these proteins. Inhibition 
studies were performed by incubating previously prepared Aβ42 samples with and without tested 
inhibitors. Specifically, inhibitors were screened in a 0.2:1 ratio with Aβ42. After incubation, samples 
were diluted to a final volume containing 1.5µM ThT. The fluorescence intensity was determined 
 41 
 
(λex = 446nm; λem = 490nm). Blanks containing inhibitor and ThT were also prepared and measured 
as references for the fluorescence-quenching effects.  
GSK3β is an isoform of glycogen synthase kinase-3 and plays an important role in tau 
hyperphosphorylation, as previously discussed. Since it is a kinase enzyme, ATP is an essential 
factor to the enzymatic function and ADP represents one important reaction product. The inhibition 
activity on GSK3β using a UHPLC-UV method is determined by measuring the ADP signal on a 
chromatographic run. In particular, to a 40µl of assay solution composed of GSK3β (2.5ng/µl), ATP 
cofactor (250µM) and GSM substrate (250µM), test inhibitors were added and the reaction was 
incubated at 30°C for 30 min before being analyzed via UHPLC/UV method. The samples were 
injected to an equilibrated reversed phase column C8, and subjected to chromatographic separation 
of ATP and ADP under optimized conditions. Parallel analysis of a blank sample was performed as 
control of ATP spontaneous hydrolysis. 
 
3.5 Results and discussions 
As reported in Table 3, all test compounds displayed an increased antioxidant activity compared to 
the reference compound, ethyl ferulate, an ester form of ferulic acid. In particular, compound 22, 
containing 3,4-dihydroxy substitution on the aromatic ring, displayed the highest activity as 
antioxidant against the autoxidation process induced by AIBN in presence of cumene as oxidative 
substrate. Furthermore, its antioxidant effect was double-confirmed in an additional experiment 
using 2,2-azobis(2-amidinopropane) dihydrochloride (AAPH) as oxidative initiator. Compound 24 
showed to be a good antioxidant as well with Kinb comparable to that of compound 22, whereas other 
analogs showed an antioxidant activity just slightly higher than the reference compound. In addition 
to Kinib values, the number of peroxy radical trapped by a single antioxidant molecule, indicated as 
“N” in Table 3, was also evaluated. Compound 22 showed the highest “N” value of the entire series 
demonstrating to be the most interesting antioxidant of the series. 
Analysis of the results related to TG2 inhibition highlights the finding that all compounds of the 
series are endowed with a poor inhibition activity towards this enzyme. These results are unexpected, 
since the trans-cinnamoyl moiety was chosen for the design of these antioxidants/TG2 inhibitors 
considering that derivatives characterized by this scaffold showed inhibition activity towards TG2 in 
low micromolar range, as reported in literature (see chapter 1). However, despite of the chemical 
features of the compounds 20-24 which closely resemble the structure of well-known TG2 inhibitors, 
their inhibition activity resulted in a millimolar range or even higher in the case of compound 23. As 
showed by the results, the activity toward TG2 depends on the nature of the substituent on the 
aromatic ring, underlining the importance role of aromatic substitution pattern for TG2 inhibition. 
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However, these results might contribute to optimize SAR studies on trans-cinnamoyl derivatives as 
TG2 inhibitors. In fact, investigations on trans-cinnamoyl inhibitors of TG2 carried out by Keillor 
and coworkers, which included cinnamoyl-pyridinyl derivatives with substituents in para and meta 
positions, drived the conclusion that a sp
2
-hybrized oxygen is crucial for biological activity. In the 
compounds series 20-24, the oxygen of OH group has a sp
3
 hybridization, which should accordingly 
possess less activity on the target.  
Considering the similarity of these derivatives with some natural compounds such as caffeic acid and 
polyphenols such as resveratrol, two natural compounds characterized by a large spectrum of 
interesting beneficial effects against AD
106
, this series of compounds was further evaluated for their 
inhibition on specific oxidative stress-related event/target involved in AD. In particular, compounds 
20-24 were investigated for their ability to inhibit GSK3β, a key enzyme in AD correlated with tau 
hyperphosphorylation, as well as against the aggregation of Aβ protein, responsible of the neuronal 
toxicity in AD, as previously discussed. As shown in the Table 3, concerning inhibition activity on 
GSK3β, although introduction of a pyridinyl group improved the inhibition activity compared to 
ethyl ferulate, all compounds, except 22, showed poor performance even at concentration of 50μM. 
Surprisingly, compound 22, structurally similar to caffeic acid with 3,4-dihydroxy substitution on 
benzene ring, turned out to be a good GSK3β inhibitor with an IC50=24.36 ± 0.01 μM. Low 
inhibition exhibited by other compounds shows that the increase of lipophilicity by introducing a 
methoxy or ethoxy group as in 20 and 21 or the presence of a single hydroxy group on the benzene 
ring as in 23 and 24, determins a decrease of inhibition potency on GSK3β. With regard to Aβ anti-
aggregation activity, the in vitro assay showed similar results, in fact, all the compounds, with the 
exception of 22, exhibited poor inhibition on Aβ42 self-aggregation with percentage of inhibition 
ranging between 5.8 and 21.5 at 50μM. Compound 22 is, again, the most active of the series with 
91.5% of inhibition at the same drug concentration and an IC50 value of 9.0 ± 1.4μM.  
Therefore, the substitution pattern on the aromatic ring of trans-cinnamoyl structure is essential to 
the antioxidant activity and even more important for the inhibition activity on Aβ self-aggregation 
and GSK3β. 
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Table 3. Results of antioxidant activity, inhibition activity on TG2, Aβ self-aggregation and GSK3β for compounds 20-
24 and Ethyl ferulate as reference compound. 
 
Compound 
Antioxidant activity 
in PhCl
a 
(T=30°C) 
TG2 IC50 
(μM) 
GSK3β 
Aβ42 self-induced 
aggregation 
Kinh/M
-1
s
-1
 N  
% inhibition 
(50μM) 
IC50 (μM) 
% inhibition 
(50μM) 
IC50 (μM) 
       
20 6.5 ± 0.2 · 10
3
 2.1 ± 0.1 688 ± 67 37.18 ± 0.14 n.d  17.5 ± 1.7 n.d  
21  5.5 ± 0.3 · 10
3
 2.1 ± 0.1 484 ± 64 39.55 ± 0.85 n.d  18.8 ± 0.5 n.d  
22  
6.2 ± 0.5 · 10
5 
2.9 ± 0.5 · 10
5b 
2.6 ± 0.3 
4.5 ± 0.2 
1001 ± 53 n.d. 24.36 ± 0.01 91.5 ± 0.5 9.0 ± 1.4 
23 5.2 ± 0.3 · 10
3
 2.0 ± 0.2 > 2000 25.18 ± 0.01 n.d  21.5 ± 5.8 n.d  
24 1.3 ± 0.2 · 10
5
 1.9 ± 0.2 266 ± 13 43.55 ± 0.01 n.d  5.8 ± 5.3 n.d  
Ethyl 
Ferulate 
4.2 ± 0.2 · 10
3
 2  9.04 ± n.d    
a 
Autoxidation experiments  using 2,2’-azobis-isobutyronitrile (AIBN) as oxidation initiator and cumene as substrat in solution of 
clorobenzene (PhCl) at 30°C 
b Autoxidation Experiment performed in Phosphate buffer 0.1M. pH 7.4, THF 3.1M, AAPH 25mM, T=30°C 
 
 
3.6 Conclusions 
Among the series of compounds 20-24, designed as TG2 inhibitors bearing antioxidant activity, 
compound 22 emerged as the most important derivative characterized by interesting biological 
profiles. Unexpectedly, all the compounds showed weak inhibitory activities towards TG2, despite 
their chemical structures are very similar to the scaffold of well-known TG2 inhibitors. However, 
these findings might contribute for a further insight of how the substituents on aromatic rings could 
significantly affect the TG2 inhibiton activity. Nevertheless, the goal related to the design of new 
multitarget ligands against AD was fulfilled by additional analysis on specific oxidative stress-
related AD targets, including GSK3β enzyme activity and Aβ self-induced aggregation process. In 
this context, compounds 20-24 showed to be mild inhibitors against amyloid aggregation and GSK3β 
enzyme activity, with exception of compound 22 which showed a much higher inhibition potency 
against the targets. Importantly, compound 22 exhibited a well-balanced micromolar inhibition 
towards both two targets (IC50 of 24µM and 9µM for GSK3β and Aβ42 self-aggregation, 
respectively), overcoming one of the challenges in multitarget ligands drug design, which is to 
achieve a drug with balanced affinity/activity toward the biological targets taken into consideration.  
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4. Fluorescent probe-linked polyamine derivatives for cell imaging studies on 
the role of transglutaminase 2 in Alzheimer’s disease 
 
Small-molecule fluorescent probes are indispensable tools for biology/biomedicine, being used as 
biomolecule labels, enzyme substrates, environmental indicators and cellular stains. Accumulating 
evidence demonstrated that the enzyme TG2, responsible of protein cross-linking catalysis, is an 
important target for AD, as illustrated in chapter 1. TG2 is also able to catalyze substrates including 
Aβ and protein tau, two proteins functioning abnormally in AD. However, elucidation concerning 
the mechanism by which TG2 is involved in AD is desired. Therefore, this chapter focuses on the 
development of fluorescent probes derived from a combination of fluorophores with TG2 inhibitors, 
designed for the purpose of cell imaging studies. These probes could be used as a biological tool for 
the investigation of the biochemical mechanisms by which TG2 exerts its role in AD. 
 
 
4.1 Fluorescence process 
Fluorescence occurs when the excited state of a molecule by absorption of light relaxes to the ground 
state through emission of a photon. In fact, absorption of light by a molecule converts the singlet 
electronic ground state (S0) to the excited state (S1, S2). The decay of the excited state can occur with 
photon emission (fluorescence) or in a nonradiative fashion. This nonradioative quenching of the 
excited state can occur through one of a variety of processes, including bond rotation or vibration, 
molecular collision, and photoinduced electron transfer (PeT). The excited state can also undergo 
intersystem crossing to the triplet excited state (T1) and subsequent relaxation by either photon 
emission (phosphorescence) or nonradiative decay. Another important pathway for decay of the 
singlet excited state involves ‘Forster resonance energy transfer’ (FRET) to an acceptor molecule: 
this process is distance-dependent and can be used to assess the proximity of labeled entities. 
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Figure 13. Jabłonski diagram showing (i) absorption of a photon leading ground state S0 to an excited state, (ii) internal 
conversion to S1, (iii) fluorescence, (iv) nonradiative decay, (v) Forster resonance energy transfer (FRET), (vi) 
intersystem crossing to T1, (vii) phosphorescence, and (viii) nonradiative decay. 
  
The key parameters of the phenomenon of fluorescence are: 
 Maximal absorption (λmax): energy between the ground state and the higher energy level. 
 Extinction coefficient (ε): the absorptivity of a molecule at λmax, defined by Lamber-Beer law. 
 Maximal emission wavelength (λem): it’s longer than λmax, because of energy losses by 
solvent reorganization or other process. 
 Strokes shift: the difference in λmax and λem. 
 Quantum yield (Φ): the ration of photons emitted and photons absorbed; the higher is 
quantum yield, more efficient is the fluorescence process. 
The utility of a particular fluorophore is dictated by its specific chemical properties, such as 
reactivity, lipophilicity, pKa and stability, and photophysical properties including λmax and λem. A 
parameter for meaningful comparisons between two fluorescent molecules is the product of the 
extinction coefficient and quantum yield (ε x Φ): this value allows comparison of the photon yield of 
different classes of fluorophores under the same light intensity. 
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Figure14. Generic absorption and emission spectra. 
 
 
4.2 Fluorophores in cell biology 
Fluorescence has been long used to visualize cell biology at many levels, from molecules to 
complete organisms. Originally, fluorescence was mainly observed from small organic dyes attached 
by means of antibodies to the protein of interest in fixed and permeabilized cells. Later, these dyes 
were improved to be able to recognize directly the biomolecular target. More recently discovered 
fluorescent proteins have enabled noninvasive imaging in living cells. Meanwhile, semiconductor 
nanocrystals have been developed with higher brightness and photostability than previous 
fluorophores, but their targeting currently remains challenging. 
- Small organic fluorophores. The use of small-molecule fluorophores began to emerge during the 
19
th
 century with the development of synthetic dyes in modern chemical industry, when the 
synthetic methodology was focused on organic colorants and their derivatives. As the industry 
evolved, the effort was shifted from dyes to drugs, leading synthetic chemist to focus on 
pharmacological agents. Today, however, there is a growing need of small-molecule 
fluorophores as tools used in biology and biomedicine. Small-molecule dyes have undergone 
optimization of wavelength range, brightness photostability and reduction in self-quenching, 
through chemical strategies such as extension of conjugation, rigidification through extra rings, 
and decoration with electron-withdrawing substituents, such as fluorines.  
- Fluorescent proteins. The first fluorescent proteins to become useful in cell biology were 
phycobiliproteins, pigments extracted from cyanobacteries. However, their applications were 
limited to antibody conjugates for cell surface labeling, due to their excessive size (200kD) that 
limit diffusion through membrane. Discovery of green fluorescent protein (GFP) represents a 
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revolutionary achievement in cell imaging. GFP alone or expressed in genetic fusions with other 
proteins enabled visualization of target proteins in a totally noninvasive way, since the 
fluorescence is generated by spontaneous cyclization and oxidation of three amino acids buried at 
the heart of the beta barrel. Following GFP, a variety of homologous fluorescent proteins with 
different colors have been discovered or developed.  
- Quantum dots. Quantum dots (QDs) are inorganic nanocrystals that fluoresce at sharp and 
discrete wavelengths depending on their size, have high extinction coefficients (10 to 100 times 
those of small fluorophores and FPs), and have good quantum yields. Crucial for biological 
applications was the development of coatings that make QDs water soluble and allow 
conjugation to antibodies. However, the large size of QDs conjugated to biomolecules prevents 
efficient traversal of intact membranes, limiting their use to permeabilized cells or extracellular 
proteins. 
Fluorophores find wide applications in cell biology studies including investigation of proteins, 
nucleic acids, enzyme activities, cell stains etc. In the context of proteins, fluorophores could be used 
in studies of protein expression, protein localization, protein diffusion and trafficking, 
conformational changes and protein turnover. Moreover, the protein activity can be manipulated 
using chromophore-activated light inactivation, generally by means of the ROS generated by the 
protein itself. With regard to enzyme activity studies, fluorogenic substrates for endogenous enzymes 
have been used to detect whether the enzyme is in active versus latent or inhibited states. The latter 
distinction is particularly important for proteases, because for many proteases, only a small fraction 
of the total pool is active. Because of the great importance of proteases in infectious diseases, 
apoptosis, inflammation, tumor development, and metastasis, several approaches have recently been 
developed for imaging protease activity in intact animals
107
. Another noteworthy example of using 
fluorophore probes to study enzymatic activity is reported by Rianes et al.
108
, where a fluorogenic 
esterase substrate was chemically coupled to RNase A. The endocytosis process followed by 
fluorescence microscopy allowed the visualization of the entire process with temporal and spatial 
resolution.  
 
 
4.3 Classes of small-molecule fluorophores 
Fluorescent compounds based on synthetic small molecules are powerful tools to visualize biological 
events in living cells and organisms. Small-molecule fluorophores are generally used in antibody 
conjugates for protein visualization in the cell environment or coupled to an enzymatic substrate to 
generate a fluorogenic substrate that allows the studies of enzyme activity. Over the years, small-
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molecule fluorophores have been subject to wide chemical modifications to generate a large variety 
of derivatives with the aim of improving their chemico-physical properties. Nevertheless, several 
“core” fluorophores with excellent spectral characteristics and high chemical stabilities can be 
identified.  
The six major classes of small-molecule fluorophores include: coumarins, fluoresceins, boron 
dipyrromethene (BODIPY) dyes, rhodamines, cyanines and benzoxadiazoles. 
 
4.3.1 Coumarins  
The coumarin scaffold is a privileged structure in organic chemistry, occurring in numerous natural 
products and pharmacological agents. Substitution at the 7-position with electron-donating groups 
yields highly fluorescent molecules. The prototypical coumarin fluorophore is 4-methyl-7-
hydroxycoumarin (4-MU), which absorbs UV light (λmax = 360 nm) and emits blue light (λem = 450 
nm). This and related compounds are the basis for many fluorescent labels, fluorescent sensors, and 
fluorogenic enzyme substrates. The pKa of 4-MU is 7.8, making the molecule sensitive to changes in 
pH under physiological conditions. The related 7-amino-4-methylcoumarin (AMC) displays similar 
spectral properties, which are constant above pH 5. Different reactive groups are compatible with 
this fluorophore and are typically attached at the position 3 or 4 to yield biomolecule labels. 
Peptidyl derivatives of AMC are widely used to measure protease activity
109
. AMC has also been 
elaborated to prepare substrates for other enzymes including histone deacetylases
110
 and esterases
111
. 
 
4.3.2 Fluoresceins 
The prototype of this class is fluorescein, synthesized in 1871; it remains one of the most widely 
used fluorophores in modern biochemical, biological and medicinal research. This dye can exist in 
seven prototropic forms, with the most biologically relevant molecular forms being the monoanion 
and the dianion that interchange with a pKa of 6.4
112
. The dianion is the most fluorescent form with a 
λmax of 490 nm and λem of 514 nm, and a quantum yield of 0.95. As in the case of the 
hydroxycoumarins, substitution with fluoro or chloro groups causes a decrease in pKa, generating 
dyes with less pH sensitivity and more photostability. A key property of fluorescein is equilibrium 
between an “open” fluorescent quinoid form and a “closed” nonfluorescent lactone. Attaching 
blocking groups on the phenolic oxygens through ester or ether bonds can modulate this equilibrium; 
this strategy has been used to prepare fluorogenic substrates for many enzymes.  
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Figure 15. Equilibrium between the open and closed forms of fluorescein. 
 
The fluorescein scaffold continues to be used to build a variety of sophisticated probes for different 
applications. Fluorescein is an extremely versatile core dye, since various modifications such as 
addition of fluoro and chloro groups can yield fluorophores with different pKa and chromatic 
properties
113
. Fluorescein can be decorated with reactive groups to yield important biomolecule 
labels
114
 and can also serve as a scaffold for preparing indicator molecules. In particular, the pH 
sensitivity of fluorescein has been exploited to prepare small-molecule pH sensors
115
. Changes in the 
pKa of fluorescein can be used as an index to report on the status of fluorescein-labeled 
biomolecules
112
. By addition of chelating moieties to the core structure, fluorescein is used also as 
ions sensor: the fluorescent complex allows the measurement of calcium ions fluxes in living cells, 
as well as detection of other ions including sodium, zinc, mercury, palladium and fluoride
116
. By 
replacing the carboxylic group on fluorescein with other substituents, the group of Urano and coll. 
discovered a series of finely tunable fluorescein-based probes with high sensitivity and has been 
applied as probe for the enzyme activity of β-galactosidase117 and further modifications allowed the 
construction of a probe used in in vivo animal model for tumor imaging
118
. 
 
4.3.3 BODIPY 
The boron difluoro dipyrromethene (BODIBY) dyes have several characteristic properties including 
neutral charge, small Stokes shift and insensitivity of fluorescence to environmental changes. The 
prototypical BODIPY dye is the tetramethyl compound, which exhibits λmax/λem = 505 nm/516 nm 
and Φ = 0.80. Derivatives characterized by this scaffold are more photostable than fluorescein and 
are especially useful where neutral charge and environmental insensitivity are advantageous. Another 
important property of this class of dyes is the tunability of wavelength through appropriate 
substitution. BODIPY dyes can thus serve as surrogates for traditional dyes such as fluorescein, 
rhodamine and many others. 
The probes built on the BODIPY scaffold is centered largely on fluorescent labels, and less 
frequently used as ions indicator. The nonpolar character of BODIPY allows incorporation into 
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lipophilic probes
119
. Moreover, the small Stokes shift of BODIPY dyes causes efficient self-
quenching of over-labeled biomolecules. This phenomenon can be utilized to create useful protease 
substrates, because proteolysis of densely labeled proteins leads to an increase in fluorescence 
intensity. One example is BODIPY-FL labeled casein used in an autoquenching assay for proteolytic 
activity of calpain, a cysteine protease 
120
. 
    
4.3.4 Rhodamines 
Rhodamines are amino counterpart of fluorescein with certain advantages over it, including lower 
pH-sensitivity, higher photostability, and tunable spectral properties. The prototypical rhodamine is 
the tetraalkylated variant sulforhodamine B. This fluorophore absorbs in the green and emits in the 
yellow (λmax/λem= 565 nm/586 nm). A more common rhodamine label is tetramethylrhodamine, 
which bears a carboxyl group on its phenyl ring that enables easier conjugation to biomolecules or 
attachment of ion-recognition motifs. In addition to modifications on the phenyl ring, changing the 
substituent patterns on the aniline nitrogens can modulate its spectral properties. Similar to 
fluoresceins, replacement of the xanthene oxygen with another atom, such as C or Si can modify 
spectral properties. 
The tunability of the rhodamine structure makes this dye class a useful scaffold for fluorescent 
probes. Accordingly, rhodamines remain the most useful basis for fluorescent labels. Rhodamine 
labels are often paired with fluorescein derivatives for FRET-based experiments because of efficient 
energy transfer between these xanthene compounds, where fluorescein is used as donor and 
rhodamine serves as FRET acceptor
121
. As in the case of fluoresceins, rhodamines that contain an 
ortho-carboxyl group on the phenyl ring exist as an equilibrated mixture of the open fluorescent 
quinoid form and a closed nonfluorescent lactone form, and acylation of the nitrogens locks the 
molecule into the lactone form. This property can be exploited to prepare fluorogenic molecules for 
enzymatic studies. In fact, N-acyl rhodamine 110 has been used to build useful caspase substrates to 
assay apoptosis
122
, also used as substrates for phophatases
123
, esterases
108
, and metal-ion catalysis in 
a cellular context
124
. 
  
4.3.5. Cyanines 
General properties of the cyanine dyes include large extinction coefficient values, highly tunable 
structures and excellent photostability. Prior to 1993, the utility of cyanines in biological research 
was primarily as a stain for cellular membranes or DNA. The development of indocarbocyanine dyes 
bearing sulfonate groups and functional groups for bioconjugation brought this dye class into the 
realm of fluorescent labels for proteins and nucleic acids.  
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The most well-known cyanine dyes in modern bioresearch are the CyDye fluorophores, 
characterized by a sulfoindocyanine structure. The CyDyes are useful biomolecular labels and are 
now the standard fluorophores for microarrays and many other analyses
125
. CyDye pairs are also 
often used for FRET experiments
126
 and can be utilized as photoswitchable probes for ultra-high-
resolution imaging
127
. 
   
4.3.6 Benzoxadiazoles 
The prototypical dye core of benzoxadiazoles is 4-nitrobenz-2-oxa-1,3-diazole (NBD). Addition of 
substituent in position 7 yields several derivatives including NBD-Cl
128
, and replacement of nitro 
group by sulfonate gives SBD-Cl. In particular, amine adducts of NBD-Cl emit in the green region of 
spectrum with λmax =465nm and λem=535nm. This low-weight fluorophore allows conjugates with 
small molecules, such as sugars, retaining the biological activity
129
.  
The environmentally sensitive fluorescence of NBD derivatives can be exploited in a variety of ways, 
including the preparation of lipid probes
129
 and novel kinase substrates. In a work by Dai et al., a 
‘caged’ form of NBD has been utilized as a sensor for protein kinase activity. In particular, enzyme 
activity of protein kinase C is critical in mitosis phase around the time point of nuclear envelope 
breakdown (NEB). In order to establish whether protein kinase C activity is present prior to, during, 
or after NEB event, a NBD-labeled peptide substrate was used since it fluoresces upon 
phosphorylation by the enzyme. In this way, the fluorescent sensor contributed to assess intracellular 
protein kinase activity at precise time intervals in reference to NEB event. 
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Table 4. Six classes of small-molecule fluorephores. 
 
A. Coumarins B. Fluoresceins 
 
 
 
 
C. BODIPY dyes D. Rhodamines 
 
 
 
 
E. Cyanines F. Benzoxadiazoles 
 
 
 
 
 
 
 
4.4 Drug design 
As illustrated in the chapter 1, accumulating evidences support the hypothesis that TG2 may be 
involved in the abnormal protein aggregation observed in AD, and there is compelling evidence from 
in vitro studies, as well as from studies on postmortem human brain tissue of AD patients and animal 
models that demonstrates a crucial role for TG2 in AD pathology. In fact, TG2 has been 
demonstrated to be colocalized in different biological samples with AD’s hallmarks – senile plaques 
and neurofibrillary tangles; moreover, Aβ and protein tau have been shown to be good substrates to 
TG2. 
Despite numerous evidences of correlations between TG2 and AD’s pathology have been reported, 
further clarification concerning how TG2 is involved in this neurodegenerative disease is desired, 
and studies to this aim are underway.  
In the attempt of investigating the mechanism by which TG2 could be involved in AD’s 
pathogenesis, we proposed the design of a series of fluorophore-linked polyamine structure based 
TG2 inhibitors and their potential utilization as probes for cell imaging studies. Fluorescence cell 
imaging has been widely used as an important tool toward understanding of cellular dynamic 
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processes in living cells and visualization of compartments or macromolecules/drugs localization 
inside fixed or living cells. The aim of constructing fluorophore-labeled TG2 inhibitors is, therefore, 
to visualize the cellular compartment in which enzymatically active TG2 is mainly present, and 
possibly to have a glimpse into the dynamic processes in which TG2 is involved. 
Polyamine chains, such as cadaverin, spermine, putrescine etc. are well-known TG2 reversible 
inhibitors with a competitive mechanism against the transamidase activity (see chapter 1). In 
literature, TG2 inhibitors based on fluorescent polyamine structure have been reported, including 
monodansylcadaverine and fluorescein-cadaverine. Therefore, polyamine with amine groups linked 
through alkyl chains of various lengths (5, 3-4-3, 3-3-3, 3-2-3 and 3-3) have been designed as ligands 
to TG2 enzyme.  
Concerning the small-molecule fluorophores, each class of derivatives is characterized by a specific 
spectral features and chemico-physical properties, such as absorption, emission, lipophilicity and 
pKa. Thus, three types of fluorophores have been selected for the labeling of polyamine chains, in 
order to have a range of choices for the identification of the most appropriate fluorescent probe, that 
shows good performance in cellular environment and allows high resolution imaging. 
On these bases, we designed and synthesized the series of fluorescent TG2 inhibitors 35-49, through 
the combination of the three fluorophores with five polyamine chains, as shown in Table 5. This 
series of compounds are supposedly to be TG2 reversible inhibitors, for the reason of the presence of 
primary amine groups, which represent good ligands to TG2 in competition with the natural 
substrate. The fluorophore moieties are coupled to the polyamine chains through formation of amide 
bond, thiourea bond or directly by nucleophilic substitution. 
The compounds will undergo in vitro assay for the assessment of inhibitory activity toward the target 
enzyme TG2; afterwards, the derivatives with positive results will be subject to further 
investigations, including activity evaluation on neuronal cells and cell imaging studies. 
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Table 5. Drug design of compounds 35-49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Methods 
The series of compounds 35-49 have been synthesized; and the biological evaluation studies are still 
in progress. 
 
4.5.1 Chemical synthesis 
The compounds 35-49 have been synthesized following the Schemes 3 and 4. 
The unprotected polyamine chains commercially available were subject to reactions shown in 
Scheme 3 to obtain an appropriate protection on amine groups. In particular, the diamine derivative 
50 was monoprotected at the amine group by reaction with tert-butyl dicarbonate (Boc2O) in 
controlled conditions; while tri-amine 51 and tetra-amines 52-54 were firstly monoprotected at the 
Compound Fluorophore Polyamine chains 
35 
 
R1= 
 
36 R2=  
37 
R3= 
 
38 
R4= 
 
39 
R5= 
 
40 
 
 
R1= 
 
41 
R2= 
 
42 
R3= 
 
43 
R4= 
 
44 
R5= 
 
45 
 
R1= 
 
46 R2=  
47 
R3= 
 
48 R4=  
49 
R5= 
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primary amine using ethyl trifluoroacetate by keeping under control the reaction conditions; 
afterwards, the remaining amine groups were protected using Boc2O. Trifluoroacetyl group was 
cleaved in basic conditions to give the desired products 55-59: mono-Boc diamine 55, di-Boc tri-
amine 56 and tri-Boc tetra-amines 57-59. 
The resulting protected polyamines were coupled to the respective fluorophore as described in 
Scheme 4. In particular, the polyamines were reacted with fluorescein isothiocyanate, where amine 
made nucleophilic attack to the electrophilic carbon of NCS to form a thiourea bond and gave the 
intermediates 60-64, which were subject to Boc deprotection to yield the final products 35-39.  
Similarly, nucleophilic substitution between polyamine and 4-chloro-7-nitrobenzofurazan gave the 
conjugates 65-69; the subsequent cleavage of Boc protection in acidic conditions gave the final 
products 40-44. Finally, synthesis of the third class of conjugates was started with the activation of 
the carboxylic acid on coumarin derivative using N-hydroxysuccinimide, followed by reaction with 
the respective polyamine to yield the intermediates 70-74. Boc deprotection gave the final products 
45-49 as chlorohydrate salts. 
 
 56 
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4.6 Conclusions 
The synthesized series of compounds 35-49 will be evaluated firstly for their potential inhibition 
effect on TG2 in both cell-free and cell-based  in vitro studies; secondly, they will be subject to cell 
imaging studies at the aim of an elucidation concerning the role of TG2 in AD’s pathological 
mechanisms. 
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SECTION II 
 
 Disrupters of ζCOP1/γCOP1 protein-protein interaction 
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1. Introduction 
Coat protein I (COPI) is a protein complex referred to as coatomer complex. It represents the major 
component of vesicles that mediate the retrograde transport from endoplasmic reticulum to Golgi 
apparatus in eukaryotic cells. In the absence of COPI, cells experience Golgi fragmentation, 
immature autophagosome accumulation, and ultimately death. A recent function-based genomic 
screen identified COPZ1, a gene encoding the coatomer complex subunit ζCOP1, as a promising 
cancer target. In fact, COPZ1 knockdown using siRNA causes tumor-specific growth inhibition 
without affecting the viability of normal cells. The mechanism of this tumor selectivity of COPZ1 
knockdown was revealed by the finding that the mRNA level of ζCOP2 is drastically reduced in 
tumor cells as consequence of gene silencing of COPZ2. Thus, while normal cells express two 
isoforms, ζCOP1 and ζCOP2, tumor cells have only ζCOP1. As a consequence, normal cells are not 
killed by COPZ1 knockdown, because the isoform ζCOP2 can functionally replace ζCOP1; while 
tumor cells cannot survive the same depletion, because of the absence of ζCOP2. Therefore, ζCOP1, 
the protein encoded by the COPZ1 gene, is crucial for the survival of tumor cells and could be a 
promising target for the development of anticancer drugs. 
This chapter focuses on the development of potential anticancer drugs capable of disrupting the main 
function of ζCOP1, which is the interaction with γCOP1 inside the coatomer complex. To this aim, a 
peptide-based inhibitor for this protein-protein interaction (PPI) has been designed and synthesized. 
In vitro evaluation of inhibition on this PPI was carried out by the method of co-immunoprecipitation. 
Fluorescently labled peptide has been developed as well to verify the penetration into cytosol. 
Potential small-molecule disruptors are under investigations. 
 
1.1 COPI secretary pathway 
The secretary pathways in eukaryotic cells are responsible for biogenesis and intracellular 
distribution of a wide range of proteins, complex carbohydrates and lipids. Membrane traffic 
between endoplasmic reticulum (ER) and the Golgi apparatus is bidirectional, known as anterograde 
and retrograde transport. This transport process is implemented by vesicular carriers, which mediate 
a continuous flux of proteins and lipids between these compartments, reflecting the transport of 
newly synthesized proteins from ER toward Golgi and the retrieval of escaped ER resident proteins.  
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Figure 16. Pathways of vesicular transport by coat proteins
130
.  
 
Anterograde and retrograde transport is mediated by two classes of cytosolic coat proteins, the 
COPII and COPI coats, respectively, which act on the membrane to capture cargo proteins into 
nascent vesicles
131
. These transport processes require a process of budding, movement, tethering, as 
well as uncoating and fusion of COPI and COPII carriers with their respective compartment.  
COPI carriers derive from assembly of a number of protein complex, named COPI coatomer, with 
the major constituents being seven subunits –coat proteins: α, β, β’, γ, δ, ε and ζCOP132. The 
assembly of coat proteins is initiated by the activation of an Arf family G protein on the membrane, 
thus, the formation of COPI vesicles is regulated by Arf1 and involves the stepwise recruitment to 
membranes of the seven coat proteins
133
. In detail, firstly, Arf1-GDP is activated by a Golgi-
localized exchange factor to replace GDP with GTP triggering a conformational change in Arf1; next, 
Arf1-GTP recruits the heptameric coatomer through a direct GTP-dependent interaction
134
, thus, 
coatomer is incorporated en bloc to the Golgi membrane
135
; finally, membrane-associated coatomer 
binds to cargo molecules and self-assembles to form a polyhedral cage
136
. Well characterized cargo 
proteins of COPI vesicles include the KDEL receptors
137
, certain p24 family members
138
 and 
SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors)
139
.  
As aforementioned, a coatomer complex structurally consists of seven subunits, named coat protein: 
α, β, β’, γ, δ, ε and ζCOP140. Each coatomer has two main subcomplexes: the γ-ζ-δ-β-COP tetrameric 
complex, which constitutes the inner layer core; and the α-β’-ε-COP trimeric complex, which forms 
the outer layer of the COPI coat.  
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Figure 17. Structure of a coatomer complex. 
 
1.2 Mechanism of coatomer recruitment to membranes 
COPI, COPII and clathrin-coated vesicles mediate vesicular transport inside an eukaryotic cell
141
. 
The transport mediated by clathrin-coated vesicles was the first secretary pathway identified and 
investigated; it contributed for the later elucidation of mechanism for the remaing two pathways: 
COPI and COPII. Clathrin-coated vesicles are responsible for traffic pathways from the plasma 
membrane to the early endosome and from the Golgi to the endosome
142
. Assembly of clathrin 
proteins requires the adaptor protein (AP) complexes. In particular, AP2 is a typical component of 
AP complexes which is well studied. The molecular mechanism of its recruitment to membranes via 
phosphatidyl inositol-4,5-bisphosphate (PtdIns4,5P2a) have been explored in considerable detail, and 
this body of work serves as a framework for exploring coat recruitment to membranes
143
.  
Based on the extreme structure homology between AP2 and COPI complexs, Goldberg and 
coworkers have pushed further on the investigation of mechanism of recruitment of coatomer via 
Arf1. According to this study
144
, the heptameric coatomer has a total of two binding sites for Arf1-
GTP: two molecules of Arf1-ATP are bound to βCOP and γCOP. Infact, using two methods 
(fluorometric assay and pull-down assay), the research group was able to find that Arf1-GTP has no 
interactions with αβ’ε-COP, it rather binds to a γζ-COP complex, in addition to interaction with βγ-
COP. This result was further confirmed by the crystal structure of γζ-COP complexed to Arf1. 
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Figure 18. Model for membrane recruitment of coatomer
144
.  
 
1.3 ζCOP 
Zeta-COP (ζCOP), reported for the first time by Kuge et al, is a 20kD coat protein that exists in 
cytosol both as free monomer and bound to the coatomer complex
140c
. In this paper, the authors used 
an anti-ζCOP antibody and found that it inhibited partially the cell-free intra-Golgi transport and 
completely blocks the formation of COPI vesicles in a free-cell system, suggesting the importance of 
this subunit.  
Inside the coatomer complex, ζCOP is bound to γCOP to form a dimer, which is further associated 
with βγ-COP giving a tetrameric structure. Later, the group of Futatsumori145 discovered the 
existance of two homologs of ζCOP (ζCOP1 and ζCOP2) and γCOP (γCOP1 and γCOP2). The 
isoforms share 75% and 80% of amino acids, respectively. This study also showed that ζCOP2 and 
γCOP2 are expressed ubiquitously suggesting their fundamental role in cellular function. 
Furthermore, yeast two-hybrid analysis indicated that γCOP1 and γCOP2 could directly interact with 
ζCOP1 and ζCOP2. The author concluded that ζCOP2 and γCOP2 can form a COPI complex in 
place of the original isoform 1, thus, these isoforms are functionally redundant. This observation has 
been confirmed with later studies conducted by Wegmann and others
146
. In fact, different 
combinations have been identified for COPI complex and ζ1-γ1, ζ1-γ2, ζ2-γ1 represent the major 
coatomer population in mammals. These isotypic coatomers are likely characterized by different 
functions in cell. Infact, significant localization differences for COPI-isoforms do exist, with a 
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preference for ζ1-γ1 and  ζ1-γ2-coatomer in the early Golgi apparatus and ζ2-γ1-coatomer in the late 
Golgi apparatus, suggesting distinct functions for coatomer isoforms
147
. 
 
1.4 ζCOP1 as a potential cancer target 
A tumor cell growth-inhibition screening conducted by Shtutman et al. identified COPZ1, the gene 
encoding ζCOP1, as a promising cancer target148. In this screening, a library of genetic inhibitors, 
including antisense cDNAs and shRNA, was employed in a growth inhition study conducted on 
multiple cell lines: MDA-MB-231 (breast cancer), PC3(prostate cancer), T24 (bladder carcinoma), 
and HT1080 (fibrosarcoma), as well as human telomerase reverse transcriptase (hTERT)-
immortalized BJ normal foreskin fibroblasts (BJ-hTERT).  
Among the genes enriched by growth-inhibition screening, gene COPZ1 which encodes the ζCOP1 
protein, emerged as an interesting target. For a deeper investigation, they used siRNAs against 
COPZ1 and other genes encoding α, β, β’, γ1/γ2, δ, ε and ζ2-COPs to reduce their RNA levels by 
90%. The results showed that knockdown of COPZ1 by siRNAs inhibited the growth of tumor cells, 
however, the growth of immortalized normal BJ-hTERT fibroblasts or normal human prostate 
epithelial cells was not inhibited by this knockdown, in contrast with siRNAs targeting other 
coatomer subunits (α, β, β’, γ, δ, ε-COPs) which did not show this tumor selectivity.  Importantly, no 
growth inhibition was observed with knockdown of COPZ2, the gene encoding the isoform ζCOP2, 
but the growth of normal cells is inhibited by the simultaneous knockdown of both COPZ1 and 
COPZ2.  
Further studies revealed that the tumor selectivity of COPZ1 knockdown was correlated with COPZ2 
downregulation observed in tumor cells. In fact, the mRNA level of ζCOP2 is drastically reduced in 
tumor cells as consequence of gene silencing of COPZ2, whereas the expression of COPZ1 and other 
COPs was relatively uniform among the normal and tumor tissues. Thus, while normal cells express 
two isoforms, ζCOP1 and ζCOP2, tumor cells have only ζCOP1. As a consequence, normal cells are 
not killed by COPZ1 knockdown, because the isoform ζCOP2 can functionally replace ζCOP1; 
whereas tumor cells cannot survive the same ζCOP1 depletion, because of absence of ζCOP2. As a 
result, normal COPZ2-expressing cells survive COPZ1 depletion, COPZ2-deficient tumor cells are 
killed by COPZ1 knockdown.  
Surprisingly, the restoration of COPZ2 expression in tumor cells did not inhibit their growth in vitro 
or in vivo, indicating that COPZ2 is not a tumor suppressor. The selective silencing of COPZ2 in 
tumor cells was later discovered to be correlated to the silencing of a tumor suppressor, microRNA-
152
149
. Infact, the first intron of the COPZ2 gene encodes a microRNA, miR-152, which was 
reported to be silenced in some cancers
150
 and displayed certain tumor-suppressive activities
151
. (The 
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COPZ1 gene also hosts a microRNA, miR-148b, which is homologous to miR-152). When miR-152 
was expressed in different tumor cell lines, their growth was inhibited. Hence, miR-152 is indeed a 
tumor suppressor, in agreement with the recent paradigm that microRNAs are key regulators of 
carcinogenesis and other phenotypic transitions. miR-152 and its host gene COPZ2 are transcribed 
from the same promoter. Hence, COPZ2 shutdown in tumor cells is a consequence of the silencing of 
tumor-suppressive miR-152, leading in its turn to tumor dependence on the COPZ1 gene.  
  
 
Figure 19. Mechanism of tumor dependence on COPZ1
152
. 
 
Tumor cells treated with siRNA against COPZ1 showed fragmentation and disappearance of Golgi 
apparatus, the same effect was observed in normal cells upon knockdown of COPZ1 and COPZ2 
together. Furthermore, tumor cells transfected with siRNA targeting COPZ1 undergo apoptosis. 
Based on these observations, our hypothesis is that a correct function of ζCOP1 is crucial for the 
survival of tumor cells and could be a promising target for the development of anticancer drugs. 
Compounds capable of interfering with the function of ζCOP1, through the inhibition of the 
association of ζCOP1 to the coatomer complex could exert selective antitumor activity. Since the 
main function of ζCOP1 is to form a dimer with γCOP1 within the coatomer complex, disrupters of 
this ζCOP1/γCOP1 protein-protein interaction could impair the correct function of ζCOP1, thus, 
being potential anticancer drugs. 
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2. Drug design 
 
Protein-protein interactions (PPIs) became recently an interesting target in the world of drug 
discovery. Over the past decades, much progress in our understanding of PPIs has been achieved. To 
date, more than 40 PPIs have been targeted
153
 and several inhibitors, most of them small molecules, 
have reached clinical trials.  
The drug design of disrupter for this ζCOP1/γCOP1 protein-protein interaction was evolved in two 
directions: i) Design of a peptide-based inhibitor based on crystal structure analysis; ii) Identification 
of potential small-molecule inhibitors of ζCOP1/γCOP1 interaction through library screening.  
For the design of peptide-based PPI inhibitor, the first efforts were focused on the computational 
analysis of the interface between the two proteins of interest. Crystal structure of ζCOP1/γCOP1 
from Protein Data Bank was used for the analysis. In silico analysis of the interface between ζCOP1 
and the Arf1/coatomer complex revealed the presence of an alpha helix in ζCOP1 close enough to 
the surface of γCOP1 to form a series of hydrogen bonds and hydrophobic interactions that hold the 
proteins together in the coatomer complex. Furthermore, a mutagenesis study conducted by Yu et 
al.
154
, identified three cluster zones on ζCOP1 that form hydrophobic bonds and salt bridges with 
γCOP1, one of which includes the alpha helix identified in computational studies. Therefore, the 
purpose is to construct a peptide that mimics this alpha helix of ζCOP1, that could function as a 
competitive inhibitor for the interaction with γCOP1, thus impairing the association of ζCOP1. 
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Figure 20. Crystal structure of dimer ζCOP1 (golden yellow) and γCOP1(blue). The three cluster zones important for the 
protein-protein interactions are colored in red, green and yellow. -Images constructed using Chimera 1.10.2. 
 
The primary sequence of this alpha-helix has been elucidated and the most important residues turned 
out to be N117 through G131(sequence NMEGLFLAVDEIVDG). In particular, E119, D126 and 
D130 of this sequence on ζCOP1 seemingly can form salt bridge with R86 and R126 on γCOP1, 
whereas F122 and L123 likely form hydrophobic interactions with L52, Y53 and M87 of γCOP1. 
Considering the excessive length of the entire sequence, and also for the reason of synthetic 
accessibility, the peptide designed will have a reduced number of residues.  
Generally, linear peptides have poor cell permeability due to the high hydrophilicity and molecular 
size, and also, peptides can lose their shape when taken out of context. Thus, chemical interventions 
to enhance cellular penetration and stabilize their bioactive structure are generally required. 
Moreover, chemical modification such as cyclization generally increases the proteolytic stability of a 
peptide. Cyclization through all-hydrocarbon bond has emerged as one such solution, conferring 
stable α-helical structure, protease resistance and cellular penetrance155. Therefore, the designed 
peptide will be cyclized through formation of all-hydrocarbon bond to give a “stapled” peptide 75, 
where the two residues not involved in interation with γCOP1 are replaced by two unnatural amino 
acids that allow the all-hydrocarbon bond formation.  
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Figure 21. Drug design of compound 75. 
In order to investigate the actual cellular penetrance of this molecule through a cell imaging 
visualization, a fluorescein-labeled staple peptide has been designed. The N-terminal of the peptide 
has been coupled to the fluorophore through an aliphatic linker to give the compound 76. 
 
 
 
These peptide-based compounds are supposedly capable of interacting with γCOP1 at the specific 
area of interface with ζCOP1, thus, inhibiting the protein-protein interaction of interest.  
Concerning the screening of potential small-molecule disrupters for the ζCOP1/γCOP1 protein-
protein interaction, in silico docking simulations have been conducted using ζCOP1 crystallographic 
structure. A library of small-molecule compounds (ZINC free database of commercially available 
compounds for virtual screening) was docked to the protein within a box created at the interface that 
defines the areas of ζCOP1 to be examined with ligand poses.  
 
 
3. Methods 
 
The compounds 75 and 76 were synthesized using the standard solid phase peptide synthesis 
procedure. Firstly, the cytotoxicity of the compounds was examined using MTS cell viability assy. 
Secondaly, the compound 75 was subject to co-immunoprecipitation assay to examine its inhibition 
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activity on ζCOP1/γCOP1 protein-protein interaction. Additionally, the fluorescent peptide was 
subject to cell fluorescence imaging studies. A number of potential small-molecule disrupters have 
been identified through docking studies. 
 
3.1 Chemical synthesis 
The compounds 75 and 76 have been synthesized following the Scheme 5. Briefly, the peptides are 
synthesized using the standard Fmoc/t-Bu solid phase peptide synthesis procedure. The Fmoc group 
on aminomethylated polystyrene resin was cleaved and the Fmoc-protected amino acids were added 
in sequence using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HBTU) 
as coupling agent in basic conditions. The olefin amino acid was coupled using a mixture of 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU)/6-Chloro-1-hydroxybenzotriazole (Cl-HOBt). Each coupling reaction was monitored by 
colorimetric test using Kaiser reagent. All-hydrocarbon bond was formed using Grubb’s catalyst in a 
ring-closing metathesis reaction. Once completed the sequence, the peptide was cleaved from resin 
using a cocktail containing trifluoroacetic acid (TFA) in the presence of scavengers. Removal of 
TFA and precipitation in cooled ether yielded the desired cyclic peptide 75.  
For the synthesis of 76, additional steps were required. Once completed the peptide sequence, Fmoc 
group on the last amino acid was removed using piperidine followed by coupling of a non-α-amino 
acid using HBTU. Fluorescein isothiocyanate was attached and the labeled peptide was cleaved from 
resin and precipitated in cooled ether to give the compound 76.  
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3.2  Cell viability assay 
The compounds 75-76 have been evaluated in cell viability assay using 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent and phenazine 
ethosulfate as electron coupling reagent. Three human tumor cell lines- Calu6 (lung 
adenocarcinoma), K562 (myelogenous leukemia) and PC3 (prostate cancer) were seeded in 96-well 
plate in triplicate and treated with drugs at concentration range of 0.1μM-200μM in incubator at 
37°C for 48h and 72h for compounds 75 and 76, respectively. A solution of MTS/phenazine 
ethosulfate was added to the plate and incubated for 4h. The colorimetric absorbance was measured 
and the data was processed. 
 
3.3 Co-immunoprecipitation assay 
The compound 75 has been evaluated for the ability of disruption toward the target protein-protein 
interaction using the co-immunoprecipitation method. Drug-treated Calu6 cells were lysed using a 
mild ion-strength lysis buffer; the protein fraction was collected and total protein concentration 
measured by bicinchoninic acid assay (BCA) assay. 1mg of protein was used for co-
immunoprecipitation. Briefly, protein sample was incubated with Protein A/G agarose beads 
followed by addition of polyclonal antibody anti-γCOP1 at 4°C. Centrifugation and removal of 
supernatant gave a pellet which was washed and suspended in SDS sample buffer for Western blot 
analysis. The two proteins of interest were detected in immunoblotting using monoclonal antibodies 
and the signal development was obtained through chemiluminescence, which was measured using an 
imaging device.  
 
3.4 Docking studies 
Small-molecule compounds available in ZINC library were docked to the crystallographic structure 
of ζCOP1 using DOCK6.5 software in flexible mode. ζCOP files were prepared for docking using 
Chimera software and the Computational Biology server. Spheres defining the molecular surface of 
ζCOP1 were generated following determined parameters and a box was created to define the areas of 
ζCOP1 to be examined with ligand poses.  
 
3.5 Cell fluorescence imaging 
PC3 cells were seeded in a 96-well plate in triplicate and treated with FITC-labeled drugs at 200μM  
for 6h and 12h. The imaging was excecuted at using fluorescence microscope. Prior to cell imaging, 
fixation using para-formaldehyde solution was performed.    
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4. Results and discussions 
 
Cell viability assay. As reported in Figure 22, compound 75 showed poor cytotoxic activity on the 
tumor cell lines examined. In fact, it inhibited only approximately 35% of tumor cell growth, at high 
concentration of 200μM on K562 cell line, while on Calu6 cells the activity was not observed. 
Compound 76 which bears a FITC moiety in addition to the same peptidic structure as compound 75, 
exhibited an improved cytotoxicity profile on tumor cells. This fluorophore-labeled peptide was 
capable to cause 67% and 32% of tumor cell growth at 200μM and 100μM, respectively. Although 
the cytotoxic potency exhibited by compound 76 is low, in comparison with the activity profile of 
analog 75, its improved potency could be due to an increased cell penetration property by addition of 
the lipophilic linker and fluorescein moiety. 
 
     
         
Figure 22. Cell viability assay results on cell lines treated with compounds 75-76. 
 
Co-immunoprecipitation assay. In literature there are very few studies on this ζCOP/γCOP protein-
protein interaction and no studies have been carried out on this PPI as a pathological target. 
Therefore, development of a method for the detection of this PPI is required. Co-immunoprecipition 
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(co-IP) assay has been applied, being one of the most widely used methods of detection for protein-
protein interactions. Co-IP method development requires the identification of appropriate cell lysis 
conditions and proper antibody to capture the bait-protein, in this case, the γCOP protein, and 
efficient antibodies for Western blot analysis. The method has been developed using a NP-400 lysis 
buffer of mild strength, and a goat polyclonal antibody against γCOP1 which was capable of 
capturing the target protein. Finally, using two mouse monoclonal antibodies, the two proteins of 
interest were efficiently detected in immunoblotting. Once the method was developed, compound 75 
has been tested on its inihibition activity on the target PPI. Calu6 cells were treated with compound 
75 at 50μM for 48h. As showed in Figure 23, unfortunately, this peptide-based compound was not 
able to disrupt the targeted PPI. Compound 76 is being tested using the same method. 
 
Figure 23. Co-IP experiments conducted on Calu6 cell line. 1) Negative control; 2) Sample treated with compound 75. 
 
Docking studies. Virtual screening using ZINC compounds library for potential small-molecule 
disrupters for the target PPI has been conducted and identified totally 17 compounds with grid score 
below -66. About 34.000.000 total compounds of the library have been firstly filtered, based on 
purchasability and Lipinski’s definitions; afterwards, compounds were docked in flexible mode into 
the ζCOP1 at the critical areas identified. Other parameters, such as Z-score representing the energy 
separation between the native fold and the average of misfolds, logP and formal charge, were taken 
into consideration for the method optimization. The identified compounds are being purchased and 
will be subject to co-immunoprecipitation assay as previously described. 
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Figure 24. Docking process representation and results. 
 
Cell fluorescence imaging studies. As shown in Figure 25, PC3 cells treated with fluorescent 
compound 76 emitted fluorescence signals. Fluorescent spots could be observed inside the cell 
indicating the actual penetrance of the compound.  
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Figure 25. Images of PC3 cells treated with fluorophore-labled peptide (compound 76) at 200μM. A) 6h treatment. B) 
12h treatment. 
 
 
5. Conclusions 
 
The compounds 75 and 76 showed poor cytotoxic activity in all the tumor cell lines examined, with 
76 that exhibited a slightly more potent tumor cell cytotoxic effect. At the time of edition of the 
present manuscript, only compound 75 has been evaluated in co-immmunoprecipitation assay, 
however, it did not show detectable inhibition activity on the ζCOP1/γCOP1 protein-protein 
interaction which is the desired target. This inactivity could be due to poor cellular penetrance of 
peptide-based compounds. However, fluorophore-labled analog 76 showed actual penetrance into the 
intracellular enviroment, as demonstrated by cell imaging studies. Further studies are underway for a 
better clarification. In particular, compound 76 will be subject to co-immunoprecipitation studies, as 
well as the small molecules identified by docking studies as potential disruptors of ζCOP1/γCOP1 
A 
B 
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protein-protein interaction. Finally, 17 compounds identified through virtual screening assays are 
currently under investigation as small-molecules disrupters of ζCOP1/γCOP1 protein-protein 
interaction. 
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Experimental section 
 
1. Chemistry 
The reactions were monitored by thin layer chromatography (TLC) (Fertigplatten SIL G 25 UV254 
MN, 0.25mm) using silica gel-coated plates. The compounds were purified by gravity or flash 
column chromatography using silica gel columns (Agela Technologies, Cleanert Silica 40-60μm, 
60Å). Melting points were determined in glass capillary tubes using Buchi 530. The synthesized 
compounds were characterized by 
1
H and 
13
C NMR spectroscopy (Varian Gemini 200/400) and ESI 
mass spectrometry (Waters ZQ 4000). All chemical shift values are reported in ppm and are relative 
to the Tetramethylsilane (TMS) as shift reference; the peaks multiplicity are given as s (singlet), br s 
(broad singlet), d (doublet), t (triplet), q (quartet) or m (multiplet). The chemicals and solvents were 
purchased from Sigma Aldrich and TCI. The purity of the peptid-based compounds was determined 
using Waters UPLC equipment and the mass spectra was produced by Waters LC-MS device. The 
compounds are named using ChemDraw Ultra 15.0. 
(E)-3-(4-nitrophenyl)-1-(pyridin-3-yl)prop-2-en-1-one (5): 3-acetylpyridine was dissolved in a 1:1 
H2O/MeOH mixture and this solution was treated with nitrobenzaldehyde (3 eq) and KOH (3 eq) and 
stirred for 30min. The mixture was filtered, and the precipitated product was washed with a 
minimum amount of ethanol to give the compound 5 as a yellow solid, which is used for the next 
step without purification. Yield：75%; mp: 182-184 °C; 1H NMR (CDCl3): δ 9.21 (s, 1H), 8.78 (d, 
1H), 8.34 (m, 3H), 7.90 (m, 3H), 7.68 (d, 1H), 7.48 (m, 1H); MS (ESI) = 255 (M+H)
+
. 
(E)-3-(4-aminophenyl)-1-(pyridin-3-yl)prop-2-en-1-one (6): The compound 5 was dissolved in 
ethanol and treated with SnCl2·5H2O (5 eq) and the reaction was stirred at 70°C for 30 min under N2. 
30 ml of H2O was added and the pH was neutralized with a solution of 5% NaHCO3. The aqueous 
phase was extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered and 
evaporated to yield a residue which was purified by flash chromatographic column using ethyl 
acetate as eluent. Yield: 57%; mp: 167-169 °C; 
1
H NMR (CDCl3): δ 9.28 (d, 1H), 8.76-8.25(m, 2H), 
7.87(d, 1H), 7.46 (m, 3H), 7.27 (d, 1H), 6.77 (d, 2H), 4.09 (s, 2H); MS (ESI) = 225 (M+H)
+
. 
(M(E)-3-(4-isothiocyanatophenyl)-1-(pyridin-3-yl)prop-2-en-1-one (7): 6 was dissolved in 
dichloromethane and the mixture was stirred under N2, a solution of 1,1’-Thiocarbonyldi-2(1H)-
pyridone in dichloromethane was added dropwise. The mixture was stirred overnight at room 
temperature. The solvent was evaporated and the residue purified by flash chromatography using a 
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mixture of EtOAc/Petroleum ether (5:5) as eluent. Yield: 62%; 
1
H NMR (CDCl3): δ 9.25 (s, 1H), 
8.71-8.33(m, 2H), 7.62(d, 1H), 7.22 (m, 3H), 7.13 (d, 1H), 6.80 (d, 2H); MS (ESI) = 267 (M+H)
+
. 
General procedure A: synthesis of azidoalkyl carboxylic acids (8-10). The appropriate 
commercially purchased bromoalkyl carboxylic acid was dissolved in anhydrous DMF, NaN3 (4 eq) 
was added and the reaction was stirred at 60°C for 5h. The reaction was diluted with H2O and the 
aqueous phase was acidified with HCl 2N and extracted with dichloromethane. The organic phase 
was washed using a saturated solution of NaCl and dried over MgSO4. Solvent evaporation under 
reduced pressure gave the desired azidoalkyl carboxylic acid which is used for the next step without 
further purification. 
3-azidopropanoic acid (8): Azide 8 was prepared from 3-bromopropionic acid using general 
procedure A and obtained as a pale yellow oil, 70% yield; 
1
H-NMR (CDCl3): δ 3.61-3.57 (t, J = 6.4 
Hz, 2H), 2.66-2.62 (t, J = 6.4 Hz, 2H). 
5-azidopentanoic acid (9): Azide 9 was prepared from 5-bromovaleric acid using general procedure 
A and obtained as a yellow-red oil, 85% yield; 
1
H NMR (CDCl3): δ 11.7 (brs, 1H), 3.27 (t, J= 6.45 
Hz, 2H), 2.36 (t, J= 6.95 Hz, 2H), 1.75 (m, 4H) 
6-azidohexanoic acid (10): Azide 10 was prepared from 6-bromohexanoic acid using general 
procedure A and obtained as a yellow-red oil, 85% yield; 
1
H NMR (CDCl3): δ 1.42 (m, 2H), 1.64 (m, 
4H), 2.36 (t, 2H, J = 7 Hz), 3.27 (t, 2H, J = 7 Hz), 9.70 (brs, 1H). 
General procedure B: Synthesis of trityl-protected hydroxamic acids (11-13). The appropriate 
azidoalkyl carboxylic acid (1 eq) was dissolved in anhydrous THF and N-methylmorpholine (1 eq) 
was added. The mixture was cooled on ice bath and stirred for 5 min. Isobutyl chloroformate (IBCF) 
(1eq) was added dropwise and the resulting mixture was stirred on ice bath for 10 min, followed by 
addition of O-tritylhydroxylamine (1 eq) and N-methylmorpholine (2 eq). The reaction was warmed 
to room temperature and stirred overnight. The mixture was poured into a solution of HCl 2N and 
extracted with EtOAc. The organic phase was dried over Na2SO4 and removal of solvent gave a 
residue, which was purified by flash chromatography using mobile phase EtOAc/petroleum ether 
(2:8). 
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3-azido-N-(trityloxy)propanamide (11): The compound 11 was prepared from 8 using general 
procedure B and isolated as white solid with 35% yield. 
1
H NMR (CDCl3): δ 1.90 (t, 2H), 2.4 (t, 2H), 
7.29–7.38 (m, 15H); MS (ESI) = 373 (M+H)+. 
5-azido-N-(trityloxy)pentanamide (12): The compound 12 was prepared from 9 using general 
procedure B and isolated as white solid with 42% yield. 
1
H NMR (CDCl3): δ 1.11–1.21 (m, 2H), 
1.44 (m, 2H), 1.77 (t, 2H), 3.24 (t, 2H), 7.29–7.38 (m, 15H); MS (ESI) = 401 (M+H)+. 
6-azido-N-(trityloxy)hexanamide (13): The compound 13 was prepared from 10 using general 
procedure B and isolated as white solid with 40% yield. 
1
H NMR (CDCl3): δ 1.50 (m, 4H), 1.35 (m, 
4H), 2.45 (t, 2H), 7.29–7.38 (m, 15H); MS (ESI) = 415 (M+H)+. 
General procedure C: Azide reduction to amines (14-16). The azide derivative (1 eq) was 
dissolved in methanol and triphenylphosphine (1.6 eq) was added followed by several drops of H2O. 
The reaction was stirred overnight at room temperature. The solvent was removed and the residue 
was purified by flash chromatography using a mixture of DCM/MeOH/ammonia solution (9:1:0.1) 
as eluent.  
3-amino-N-(trityloxy)propanamide (14): The compound 14 was obtained from 11 using general 
procedure C and isolated as white solid with 55% yield. 
1
H NMR (CDCl3): δ 2.85 (t, 2H), 2.13 (t, 
2H), 7.25–7.45 (m, 15H); MS (ESI) = 347 (M+H)+. 
5-amino-N-(trityloxy)pentanamide (15): The compound 15 was obtained from 12 using general 
procedure C and isolated as white solid with 62% yield. 
1
H NMR (CDCl3): δ 1.08–1.25 (m, 4H), 
2.53 (t, 2H), 3.34 (t, 2H), 3.47 (brs, 2H), 7.23–7.40 (m, 15H); MS (ESI) = 375 (M+H)+. 
6-amino-N-(trityloxy)hexanamide (16): The compound 16 was obtained from 13 using general 
procedure C and isolated as white solid with 65% yield. 
1
H NMR (CDCl3): δ 1.38–1.55 (m, 6H), 
2.63 (t, 2H), 3.28 (t, 2H), 3.50 (brs, 2H), 7.20–7.42 (m, 15H); MS (ESI) = 389 (M+H)+. 
General procedure D: Synthesis of thiourea bond (17-19): Compound 7 was dissolved in DCM 
and the appropriate amine derivative was added. The resulting mixture was stirred overnight at room 
temperature. The solvent was evaporated and the residue was purified using flash chromatography 
using a mixture of EtOAc/petroleum ether (6:4) to afford the desired product. 
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(E)-3-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)-N-(trityloxy)propanamide 
(17): The compound 17 was prepared from 14 using general procedure D; yellow oil, yield 65%; 
1
H 
NMR (CDCl3): δ 2.95 (t, 2H), 3.17 (t, 2H), 6.75 (d, 2H), 7.15-7.47 (m, 21H), 8.17-8.79 (m, 2H), 9.23 
(s, 1H); MS (ESI) = 614 (M+H)
+
. 
(E)-5-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)-N-(trityloxy)pentanamide 
(18): The compound 18 was prepared from 15 using general procedure D; yellow oil, yield 62%; 
1
H 
NMR (CDCl3): δ 1.48-1.57 (m, 4H), 2.35 (t, 2H), 3.47 (t, 2H), 6.62 (d, 2H), 7.24-7.45 (m, 20H), 
8.20-8.39 (m, 2H), 9.10 (s, 1H); MS (ESI) = 641 (M+H)
+
. 
(E)-6-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)-N-(trityloxy)hexanamide 
(19): The compound 19 was prepared from 16 using general procedure D; yellow oil, 60% yield; 
1
H 
NMR (CDCl3): δ 1.43-1.62 (m, 6H), 2.35 (t, 2H), 3.47 (t, 2H), 6.65 (d, 2H), 7.25-7.67 (m, 20H), 
8.37-8.89 (m, 2H), 9.17 (s, 1H); MS (ESI) = 655(M+H)
+
. 
General procedure E: Trityl deprotection to afford hydroxamic acids (2-4): The trityl-protected 
derivative was dissolved in anhydrous DCM and TFA was added, the color of the reaction turned 
into intense yellow. Triethylsilane was added dropwise until the reaction returned to the original 
color. The reaction was monitored by TLC. Once completed, the reaction mixture was concentrated 
under vacuum to afford a brown-red residue, which was dissolved in a minimum amount of DCM 
and the product was precipitated from ether. The precipitated was collected by filtration and finally 
washed with ether.  
(E)-N-hydroxy-3-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)propanamide 
(2):  The compound 2 was prepared from 17 using general procedure E and obtained as a yellow-red 
solid with 41% yield. 
1
H NMR (CDCl3): δ 2.56 (t, 2H), 3.02 (t, 2H), 6.68 (d, 2H), 7.35-7.77 (m, 5H), 
8.17-8.79 (m, 2H), 9.12 (s, 1H); 7.35 (brs, 2H); MS (ESI) = 371 (M+H)
+
. 
(E)-N-hydroxy-5-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)pentanamide 
(3): The compound 3 was prepared from 18 using general procedure E and obtained as a yellow-red 
solid with 54% yield. 
1
H NMR (CDCl3): δ 1.43-1.52 (m, 4H), 2.47 (t, 2H), 3.49 (t, 2H), 6.74 (d, 2H), 
7.30-7.41 (m, 4H), 8.37-8.48 (m, 3H), 9.20 (s, 1H); MS (ESI) = 399 (M+H)
+
. 
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(E)-N-hydroxy-6-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)hexanamide (4): 
The compound 4 was prepared from 19 using general procedure E and obtained as a brown-red solid 
with 59% yield. 
1
H NMR (CDCl3): δ 1.76-2.02 (m, 6H), 2.45 (t, 2H), 3.60 (t, 2H), 7.02 (d, 2H), 7.25-
7.67 (m, 5H), 8.25-8.79 (m, 2H), 9.07 (s, 1H), 7.45 (brs, 2H); MS (ESI) = 413 (M+H)
+
. 
Synthesis of pyridinium-p-toluenesulfonate: p-toluenesulfonic acid monohydride (1 eq) was added 
to a solution of pyridine (3 eq) and the mixture was stirred at room temperature for 20 min, pyridine 
in excess was removed on rotavapor to give pyridinium-p-toluenesulfonate as a white solid in 
quantitative yield. M.P.=121°C 
General procedure F: Tetrahydropyranyl ethers 25-29. 3,4-dihydro-2H-pyran (10 eq) was added 
dropwise to a solution of the appropriate aldehyde (1eq) in dichloromethane. Pyridinium-p-
toluenesulfonate (2 eq) was added and the reaction was stirred at room temperature for 12h. Upon 
completion of the reaction, the mixture was washed with saturated NaHCO3 solution, H2O and brine. 
The organic phase was dried over Na2SO4 and concentrated at reduced pressure to give a residue, 
which was purified by flash chromatography. 
3-methoxy-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (25): The compound 25 was 
prepared following general procedure F and obtained as yellow oil in 62% yield. Mobile phase for 
flash chromatography: DCM/MeOH (9:1); 
1
H-NMR (CDCl3, 400 MHz) δ1.51-1.56 (m, 1H), 1.63-
1.66 (m, 2H), 1.79-1.83 (m, 1H), 2.10.-2.14 (m, 1H), 3.48-3.54 (m, 1H), 3.83-3.89 (m, 1H), 3.95 (s, 
3H), 5.31-5.37 (m, 1H), 7.18 (d, 2H), 7.62 (s, 1H), 7.71 (d, 1H), 9.74 (s, 1H).  
3-ethoxy-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (26): The compound 26 was prepared 
following general procedure F and obtained as yellow oil in 77% yield. Mobile phase for flash 
chromatography: DCM/MeOH (9:1); 
1
H-NMR (CDCl3, 400 MHz) δ1.42-1.56 (m, 3H), 1.61-1.71 (m, 
2H), 1.72-1.79 (m, 1H), 2.05-2.12 (m, 1H), 3.33-3.41 (m, 1H), 3.78-3.85 (m, 1H), 3.91 (s, 3H), 5.22-
5.27 (m, 1H), 7.11 (d, 2H), 7.67 (s, 1H), 7.81 (d, 1H), 9.88 (s, 1H). 
3,4-bis((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (27): The compound 27 was prepared 
following general procedure F and obtained as yellow oil in 45% yield. Mobile phase for flash 
chromatography: DCM/MeOH (9.5: 0.5); 
1
H-NMR (CDCl3, 400 MHz) δ 1.59-1.94 (m, 8H), 2.01.-
2.14 (m, 2H), 3.59-3.72 (m, 2H), 3.82-3.96 (m, 2H), 5.39-5.41 (m, 2H), 7.13 (d, 2H), 7.44 (s, 1H), 
7.77 (d, 1H), 9.63 (s, 1H). 
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4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (28): The compound 28 was prepared following 
general procedure F and obtained as yellow oil in 80% yield. Mobile phase for flash chromatography: 
Petroleum ether/ EtOAc (9: 1); 
1
H-NMR (CDCl3, 400 MHz) δ 1.55-1.61 (m, 1H), 1.60-1.68 (m, 2H), 
1.80-1.88 (m, 1H), 2.04.-2.10 (m, 1H), 3.55-3.61 (m, 1H), 3.94-4.01 (m, 1H), 5.33-5.37 (m, 1H), 
7.17 (d, 2H), 7.98 (d, 2H), 9.87 (s, 1H). 
3-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (29): The compound 29 was prepared following 
general procedure F and obtained as yellow oil in 85% yield. Mobile phase for flash chromatography: 
Petroleum ether/ EtOAc (9: 1); 
1
H-NMR (CDCl3, 400 MHz) δ1.55-1.61 (m, 1H), 1.65-1.72 (m, 2H), 
1.83-1.88 (m, 1H), 1.95-2.05(m, 1H), 3.60-3.66 (m, 1H), 3.80-3.86 (m, 1H), 5.50-5.54 (m, 1H), 7.15-
7.18 (m, 2H), 7.79-7.84 (m, 2H), 9.97 (s, 1H). 
General procedure G: Aldol condensation to give derivatives 30-34. The corresponding 
tetrahydropyranyl ether 25-29 (1 eq) was suspended in NaOH 2.5M and 3-acetylpyridine (1 eq) was 
added dropwise. The mixture was stirred at room temperature for 12h, the reaction color switched 
from yellow to red/orange. The solvent was removed and the residue was purified by flash 
chromatography. 
(E)-3-(3-methoxy-4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-1-(pyridin-3-yl)prop-2-en-1-one 
(30): The compound 30 was prepared from 25 using general procedure G and obtained as a yellow 
oil with 51% yield. Mobile phase for flash chromatography: DCM/MeOH (9:1) 
1
H NMR (CDCl3, 
400MHz): δ1.61-1.68 (m, 2H), 1.77-1.88 (m, 2H), 1.91-2.01 (m, 2H), 3.52-3.59 (m, 1H), 3.81-3.87 
(m, 1H), 3.91 (s, 3H), 5.29-5.38 (m, 1H), 6.84 (d, 1H), 7.28-7.51 (d, 4H), 7.82-7.95 (d, 1H), 8.49 (d, 
1H), 8.86 (m, 1H), 9.35 (d, 1H). 
(E)-3-(3-ethoxy-4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-1-(pyridin-3-yl)prop-2-en-1-one (31): 
The compound 31 was prepared from 26 using general procedure G and obtained as a yellow oil with 
60% yield. Mobile phase for flash chromatography: DCM/MeOH (9:1) 
1
H NMR (CDCl3, 400MHz): 
δ1.42-1.56 (m, 4H), 1.61-1.71 (m, 2H), 1.72-1.79 (m, 1H), 2.05-2.12 (m, 1H), 3.33-3.41 (m, 1H), 
3.78-3.85 (m, 1H), 3.91 (s, 3H), 5.22-5.27 (m, 1H), 6.84 (d, 1H), 7.28-7.51 (d, 4H), 7.82-7.95 (d, 1H), 
8.49 (d, 1H), 8.86 (m, 1H), 9.35 (d, 1H). 
(E)-3-(3,4-bis((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-1-(pyridin-3-yl)prop-2-en-1-one (32): The 
compound 32 was prepared from 27 using general procedure G and obtained as a yellow oil with 
45% yield. Mobile phase for flash chromatography: DCM/MeOH (9:1) 
1
H NMR (CDCl3, 400MHz): 
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δ1.54-1.89 (m, 8H), 2.06.-2.47 (m, 4H), 3.77-3.95 (m, 2H), 5.30-5.51 (m, 2H), 5.81-5.92 (m, 2H), 
6.89 (d, 1H), 7.31-7.55 (d, 4H), 7.83-7.95 (d, 1H), 8.44 (d, 1H), 8.91 (m, 1H), 9.32 (d, 1H). 
(E)-1-(pyridin-3-yl)-3-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)prop-2-en-1-one (33): The 
compound 33 was prepared from 28 using general procedure G and obtained as a yellow oil with 
38% yield. Mobile phase for flash chromatography: DCM/toluene/MeOH (8:1:1). 
1
H NMR (CDCl3, 
400MHz): δ1.49-1.57 (m, 2H), 1.64-1.69 (m, 2H), 1.77-1.99 (m, 2H), 3.79-3.84 (m, 1H), 3.91-3.95 
(m, 1H), 5.89-5.94 (m, 1H), 6.92 (d, 1H), 7.34-7.58 (d, 4H), 7.84-91 (d, 2H), 8.32 (d, 1H), 8.82 (m, 
1H), 9.23 (d, 1H). 
(E)-1-(pyridin-3-yl)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)prop-2-en-1-one (34): The 
compound 34 was prepared from 29 using general procedure G and obtained as a yellow oil with 
42% yield. Mobile phase for flash chromatography: DCM/MeOH (9.7:0.3). 
1
H NMR (CDCl3, 
400MHz): δ1.53-1.62 (m, 2H), 1.61-1.73 (m, 2H), 1.81-1.95 (m, 2H), 3.61-3.64 (m, 1H), 3.89-3.94 
(m, 1H), 5.67-5.71 (m, 1H), 6.72 (d, 1H), 6.98 (d, 1H), 7.13-7.33 (m, 4H), 7.60 (d, 1H), 7.82 (m, 1H), 
8.35 (d, 1H), 8.81 (d, 1H). 
General procedure H: Deprotection on hydroxyl groups to give products 20-24. The appropriate 
THP-protected derivative 30-34 was dissolved in MeOH and p-toluenesulfonic acid in catalytic 
amount was added. The solution was stirred at room temperature for 12h. The solvent was removed 
and the residue purified by flash chromatography. 
(E)-3-(4-hydroxy-3-methoxyphenyl)-1-(pyridin-3-yl)prop-2-en-1-one (20): The compound 20 
was prepared from 30 using general procedure H and obtained as a yellow oil with 39% yield. 
Mobile phase for flash chromatography: DCM/MeOH (9.8:0.2). 
1
H NMR (CD3OD, 400 MHz): δ3.98 
(s, 3H), 6.97 (d, 1H), 7.15 (d, 1H), 7.23-7.27 (m, 2H), 7.34 (d, 1H), 7.48 (m, 1H), 7.80 (m, 1H), 8.30 
(m, 1H), 8.81 (m, 1H), 8.23 (m, 1H); 
13
C-NMR (CD3OD, 100 MHz): δ56.00, 110.80, 115.09, 118.88, 
123.92, 126.89, 136.02, 146.50, 147.04, 148.99, 149.42, 152.67, 189.01; MS (ESI
+
): 256 (M+H)
+
. 
(E)-3-(3-ethoxy-4-hydroxyphenyl)-1-(pyridin-3-yl)prop-2-en-1-one (21): The compound 21 was 
prepared from 31 using general procedure H and obtained as a yellow oil with 30% yield. Mobile 
phase for flash chromatography: DCM/toluene/MeOH (9:0.9:0.1). 
1
H NMR (CDCl3, 400 MHz): 
δ1.50 (t, 3H), 4.21 (q, 2H), 6.98 (d, 1H), 7.13 (d, 1H), 7.14-7.34 (m, 3H), 7.47 (d, 1H), 7.77 (d, 1H), 
8.29 (m, 1H), 8.80 (m, 1H), 9.23 (m, 1H); 
13
C NMR (CDCl3, 100 MHz): δ14.78, 64.71, 110.94, 
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114.98, 118.89, 123.75, 126.92, 136.00, 146.24, 146.56, 148.99, 149.48, 152.75, 189.04; MS (ESI
+
): 
270 (M+H)
+
. 
(E)-3-(3,4-dihydroxyphenyl)-1-(pyridin-3-yl)prop-2-en-1-one (22): The compound 22 was 
prepared from 32 using general procedure H and obtained as a yellow oil with 22% yield. Mobile 
phase for flash chromatography: DCM/MeOH (9.5:0.5). 
1
H NMR (CD3OD, 400 MHz): δ6.95 (d, 2H), 
734-7.44 (m, 3H), 7.87 (d, 1H), 8.32 (m, 1H), 8.91(d, 1H), 9.29 (d, 1H); MS (ESI
+
): 242 (M+H)
+
. 
(E)-3-(4-hydroxyphenyl)-1-(pyridin-3-yl)prop-2-en-1-one (23): The compound 23 was prepared 
from 33 using general procedure H and obtained as a yellow oil with 38% yield. Mobile phase for 
flash chromatography: DCM/MeOH (9.5:0.5). 
1
H NMR (CD3OD, 400 MHz): δ6.91 (d, 2H), 7.38-
7.58 (m, 4H), 7.82 (d, 1H), 8.22 (m, 1H), 8.81 (d, 1H), 9.23 (d, 1H); MS (ESI
+
): 226 (M+H)
+
. 
(E)-3-(3-hydroxyphenyl)-1-(pyridin-3-yl)prop-2-en-1-one (24): The compound 24 was prepared 
from 34 using general procedure H and obtained as a yellow oil with 21% yield. Mobile phase for 
flash chromatography: DCM/MeOH (9.5:0.5). 
1
H NMR (CD3OD, 400 MHz): δ6.69 (d, 1H), 7.02 (d, 
1H), 7.11-7.35 (m, 4H), 7.69 (d, 1H), 7.91 (m, 1H), 8.44 (d, 1H), 8.98 (d, 1H); MS (ESI
+
): 226 
(M+H)
+
. 
General procedure for the synthesis of compound 55. The monoprotected cadaverine 55 was 
obtained from reaction of 1,5-diaminopentane (cadaverine) with Boc2O in equimolar ratio. The 
solution of 1,5-diaminopentane in MeOH/triethylamine was cooled down to 0°C and stirred for 
10min, followed by addition of Boc2O solution dropwise under nitrogen. The resulting mixture was 
allowed to warm to room temperature and stirred overnight. The solvent was evaporated and the 
residue dissolved in DCM and washed with H2O. Concentration of the organic phase gave a residue 
which was purified by gravity chromatography using mixture of DCM/MeOH/ammonia hydroxide 
(8:2:0.1) as mobile phase. Results of structure analysis were in agreement with data reported in 
literature. 
General procedure for the synthesis of compounds 56-59. Ethyl trifluoroacetate (1eq) was added 
dropwise to a solution of polyamine 51-55 (1 eq) in MeOH at -78°C under nitrogen. The mixture 
was stirred for 30 min followed by addition of Boc2O solution dropwise. The reaction was allowed to 
warm to room temperature and stirred for 16h. Afterwards, 8 ml of H2O and 3 ml of concentrated 
NaOH were added and the reaction was continued at room temperature for 20h. The solvent was 
removed and the residue was dissolved in DCM and washed with H2O. The organic layer was dried 
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over Na2SO4 and concentrated to give yellow oil, followed by purification with flash 
chromatography: mobile phase DCM/MeOH/ammonia hydroxide (9:1:0.1). Results of structure 
analysis were in agreement with data reported in literature. 
General procedure I: synthesis of compounds 60-64. To a solution of fluorescein isothiocyanate (1 
eq) and the appropriate Boc-protected polyamine 55-59 (1 eq) in DMF, triethylamine (1 eq) was 
added and the solution was stirred at room temperature for 12h. The residue obtained after the 
removal of solvent was purified by flash chromatography using a mixture of DCM/MeOH/formic 
acid (9.5:0.5:0.01). 
5-(3-(5-((tert-butoxycarbonyl)amino)pentyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-
yl)benzoic acid (60). The compound 60 was prepared following the general procedure I and isolated 
as yellow oil in 65% yield. 
5-(3-(3-((tert-butoxycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)propyl) 
thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (61). The compound 61 was 
prepared following the general procedure I and isolated as yellow oil in 75% yield. 
5-(3-(9,12-bis(tert-butoxycarbonyl)-2,2-dimethyl-4-oxo-3-oxa-5,9,12-triazapentadecan-15-
yl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (62). The compound 62 was 
prepared following the general procedure I and isolated as yellow oil in 73% yield. 
5-(3-(3-((tert-butoxycarbonyl)(3-((tert-butoxycarbonyl)(3-(methylamino)propyl)amino)propyl) 
amino)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (63). The 
compound 63 was prepared following the general procedure I and isolated as yellow oil in 76% yield. 
5-(3-(9,14-bis(tert-butoxycarbonyl)-2,2-dimethyl-4-oxo-3-oxa-5,9,14-triazaheptadecan-17-
yl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (64). The compound 64 was 
prepared following the general procedure I and isolated as yellow oil in 80% yield. 
General procedure J: synthesis of compounds 65-69. The solution of 4-chloro-7-
nitrobenzofurazan (0.5 eq) and the respective Boc-protected polyamine 55-59 (1 eq) in 5ml of 
dioxane was stirred at room temperature for 12h, protected from exposure to the light. The solvent 
was evaporated and the resulting residue was purified by flash chromatography using a mixture of 
petroleum ether/ethyl acetate (6:4) as mobile phase. 
 85 
 
tert-butyl (5-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)pentyl)carbamate (65). The 
compound 65 was prepared following the general procedure J and isolated as yellow solid in 65% 
yield. 
tert-butyl(3-((tert-butoxycarbonyl)amino)propyl)(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4- 
yl)amino)propyl)carbamate (66). The compound 66 was prepared following the general procedure 
J and isolated as yellow solid in 85% yield. 
tert-butyl(2-((tert-butoxycarbonyl)(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propyl) 
amino)ethyl)(3-((tert-butoxycarbonyl)amino)propyl)carbamate (67). The compound 67 was 
prepared following the general procedure J and isolated as yellow solid in 89% yield.  
tert-butyl(3-((tert-butoxycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)propyl)(3-
((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propyl)carbamate (68). The compound 68 was 
prepared following the general procedure J and isolated as yellow solid in 88% yield. 
tert-butyl(4-((tert-butoxycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)butyl)(3-((7-
nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propyl)carbamate (69). The compound 68 was 
prepared following the general procedure J and isolated as yellow solid in 81% yield. 
General procedure K: synthesis of compounds 70-74. 7-Amino-4-methyl-3-coumarinylacetic acid 
(1 eq) and N-hydroxysuccinimide (1.5 eq) were dissolved in DMF and the solution was cooled on ice 
bath. Dicyclohexylcarbodiimide (1.5 eq) was added and the reaction was allowed to warm to room 
temperature and stirred for 3h. Removal of solvent gave a brown solid which was used directly for 
the next step: the solid was dissolved in DMF at 0°C, Boc-protected polyamine (1.2 eq) and DIPEA 
(1.2 eq) were added in sequence and the mixture was stirred at room temperature for 16h. The 
solvent was evaporated to give a residue which was purified by flash chromatography using a 
mixture of EtOAc/Toluene/petroleum ether (8:1:1) as mobile phase.  
tert-butyl (5-(2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)acetamido)pentyl)carbamate (70). 
The compound 70 was prepared following the general procedure K and isolated as yellow oil in 55% 
yield. 
tert-butyl(3-(2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)acetamido)propyl)(3-((tert-
butoxycarbonyl)amino)propyl)carbamate (71). The compound 71 was prepared following the 
general procedure K and isolated as yellow oil in 83% yield. 
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tert-butyl(2-((3-(2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)acetamido)propyl)(tert-
butoxycarbonyl)amino)ethyl)(3-((tert-butoxycarbonyl)amino)propyl)carbamate (72). The 
compound 72 was prepared following the general procedure K and isolated as yellow oil in 89% 
yield. 
tert-butyl(3-((3-(2-(6-amino-1-methyl-3-oxo-3,4-dihydronaphthalen-2-yl)acetamido)propyl) 
(tert-butoxycarbonyl)amino)propyl)(3-((tert-butoxycarbonyl)amino)propyl)carbamate (73). 
The compound 73 was prepared following the general procedure K and isolated as yellow oil in 90% 
yield. 
tert-butyl(3-(2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)acetamido)propyl)(4-((tert-
butoxycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)butyl)carbamate (74). The 
compound 74 was prepared following the general procedure K and isolated as yellow oil in 92% 
yield. 
General procedure L: Cleavage of Boc group for the synthesis of compounds 35-49. To a 
solution of the appropriate conjugate fluorophore/Boc-polyamine in methanol, HCl 2N was added 
and the resulting mixture was stirred for 12h at room temperature. The solvent was removed and the 
residue was dissolved in H2O and washed with ethyl acetate. The aqueous phase was evaporated and 
the resulting residue was dried at vacuum pump to give the final products 35-49 as chlorohydrate 
salts. 
5-(3-(5-aminopentyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (35): The 
compound 35 was obtained from 60 using general procedure L and isolated as yellow oil with 75% 
yield. 
1
H-NMR (400 MHz, CDCl3): δ1.26-1.29 (m, 2H), 1.50-1.54 (m, 4H), 2.00 (brs, 1H), 2.65 (t, 
2H), 3.67 (t, 2H), 4.00 (brs, 1H), 5.06-5.11 (m, 3H), 5.82-5.84 (m, 1H), 6.44-6.47 (m, 2H), 6.64-6.68 
(m, 1H), 6.97-6.98 (m, 2H), 7.20-7.34 (m, 4H), 7.81 (d,1H), 11.00 (brs, 1H). 
 
5-(3-(3-((3-aminopropyl)amino)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-
yl)benzoic acid (36). The compound 36 was obtained from 61 using general procedure L and 
isolated as yellow oil with 72% yield; 
1
H-NMR (CDCl3, 400 MHz): δ1.93-1.94 (m, 2H), 2-93-2.98 
(m, 8H), 6.81 (s, 1H), 7.12 (d, 1H), 7.21-7.24 (m, 2H), 7.59-7.61 (m, 1H), 8.05 (s, 1H); MS(ESI): 
522(M+H)
+
. 
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5-(3-(3-((2-((3-aminopropyl)amino)ethyl)amino)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-
xanthen-9-yl)benzoic acid (37). The compound 37 was obtained from 62 using general procedure L 
and isolated as yellow oil with 72% yield. 
1
H-NMR (CDCl3, 400 MHz): δ 1.97-2.04 (m, 4H), 2.99 (t, 
2H), 3.01-3.16 (m 4H), 3.18-3.40 (m, 4H), 3.60 (t, 2H), 6.74-6.79 (m, 4H), 7.04 (d, 1H), 7.22 (d, 1H), 
7.63 (d, 1H), 8.11 (s, 1H); MS(ESI): 565 (M+H)
+
. 
5-(3-(3-((3-((3-aminopropyl)amino)propyl)amino)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-
xanthen-9-yl)benzoic acid (38). The compound 38 was obtained from 63 using general procedure L 
and isolated as yellow oil with 71% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.94-2.02 (m, 6H), 2.94-
3.06 (m, 10H), 3.62 (t, 2H), 6.79-6.82 (m, 4H), 7.14 (d, 1H), 7.23 (d, 1H), 7.62 (d, 1H), 8.05 (s, 1H); 
MS(ESI): 579 (M+H)
+
. 
5-(3-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-
xanthen-9-yl)benzoic acid (39). The compound 39 was obtained from 64 using general procedure L 
and isolated as yellow oil with 71% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.91-2.05 (m, 6H), 2.90-
3.10 (m, 12H), 3.71 (t, 2H), 6.72-6.81 (m, 4H), 7.17 (d, 1H), 7.26 (d, 1H), 7.69 (d, 1H), 8.01 (s, 1H); 
MS(ESI): 593 (M+H)
+
. 
N1-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)pentane-1,5-diamine (40). The compound 40 was 
obtained from 65 using general procedure L and isolated as yellow solid with 75% yield. 
1
H-NMR 
(400 MHz, CDCl3): δ1.39-1.44 (m, 2H), 1.59-1.74 (m, 4H), 2.88-2.91 (t, 2H), 3.44 (brs, 2H), 6.17-
6.20 (d, 1H), 8.29-8.31 (d, 1H). 
 
N1-(3-aminopropyl)-N3-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)propane-1,3-diamine (41). The 
compound 41 was obtained from 66 using general procedure L and isolated as yellow solid with 83% 
yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.95-2.09 (m, 4H), 2.97 (t, 2H), 3.06 (t, 2H), 3.11 (t, 2H), 3.58 
(t, 2H), 6.24 (d, 1H), 8.36 (d, 1H).; MS(ESI): 295 (M+H)
+
. 
N1-(2-((3-aminopropyl)amino)ethyl)-N3-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)propane-1,3-
diamine (42). The compound 42 was obtained from 67 using general procedure L and isolated as 
yellow solid with 88% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.97-2.13 (m, 4H), 2.99 (t, 2H), 3.10 (t, 
2H), 3.19 (t, 2H), 3.36-3.40 (m, 4H), 3.59 (t, 2H), 6.23 (d, 1H), 8.33 (d, 1H).; MS(ESI): 339 (M+H)
+
. 
N1-(3-aminopropyl)-N3-(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propyl)propane-1,3-
diamine (43). The compound 43 was obtained from 68 using general procedure L and isolated as 
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yellow solid with 86% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.99-2.10 (m, 8H), 2.97-3.14 (m, 8H), 
3.10 (t, 2H), 6.29 (d, 1H), 8.40 (d, 1H); MS(ESI): 352 (M+H)
+
. 
N1-(3-aminopropyl)-N4-(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propyl)butane-1,4-
diamine (44). The compound 44 was obtained from 69 using general procedure L and isolated as 
yellow solid with 88% yield. 1H-NMR (CDCl3, 400 MHz): δ1.95-2.07 (m, 10H), 2.96-3.19 (m, 8H), 
3.15 (t, 2H), 6.33(d,1H), 8.49(d,1H); MS(ESI): 366 (M+H)
+
.  
2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)-N-(5-aminopentyl)acetamide (45). The compound 
45 was obtained from 70 using general procedure L and isolated as red solid with 80% yield. 
1
H-
NMR (400 MHz, CDCl3): δ1.15-1.21 (m, 2H), 1.31-1.35 (t, 2H), 1.45-1.50 (m, 2H), 2.15 (s, 3H), 
2.77-2.81(t,2H), 2.97-3.00(t,2H), 3.36(s,2H), 7.10-7.15 (t, 2H), 7.59-7.61 (d, 1H). 
2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)-N-(3-((3-aminopropyl)amino)propyl)acetamide 
(46). The compound 46 was obtained from 71 using general procedure L and isolated as red solid 
with 78% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.82-1.85 (m, 2H), 1.92-1.97 (m, 2H), 2.37 (s, 3H), 
2.99-3.07 (m, 4H), 3.32-3.36 (m, 4H), 3.57 (s, 2H), 7.16 (m, 2H), 7.78 (d, 1H); MS(ESI): 347 
(M+H)
+
.  
2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)-N-(3-((2-((3-aminopropyl) amino)ethyl)amino) 
propyl)acetamide (47). The compound 47 was obtained from 72 using general procedure L and 
isolated as red solid with 86% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.80-1.83 (m, 2H), 1.98-2.01 (m, 
2H), 2.31 (s, 3H), 2.97-3.05 (m, 4H), 3.12 (t, 2H), 3.22 (t,2 H), 3.32-3.35 (m, 4H), 3.53 (s, 2H), 7.11 
(m, 2H), 7.72 (d, 1H); MS(ESI): 390 (M+H)
+
. 
2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)-N-(3-((3-((3-aminopropyl)amino)propyl)amino) 
propyl)acetamide (48). The compound 48 was obtained from 73 using general procedure L and 
isolated as red solid with 87% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.78-1.81 (m, 4H), 1.94-2.01 (m, 
2H), 2.35 (s, 3H), 2.91-3.00 (m, 4H), 3.15 (t, 2H), 3.19 (t,2 H), 3.31-3.36 (m, 4H), 3.57 (s, 2H), 7.21 
(m, 2H), 7.82 (d, 1H); MS(ESI): 404 (M+H)
+
. 
2-(7-amino-4-methyl-2-oxo-2H-chromen-3-yl)-N-(3-((4-((3-aminopropyl)amino)butyl)amino) 
propyl)acetamide (49). The compound 49 was obtained from 74 using general procedure L and 
isolated as red solid with 91% yield. 
1
H-NMR (CDCl3, 400 MHz): δ1.73-1.80 (m, 6H), 1.92-1.99 (m, 
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2H), 2.31 (s, 3H), 2.94-3.02 (m, 4H), 3.19 (t, 2H), 3.21 (t,2 H), 3.32-3.37 (m, 4H), 3.61 (s, 2H), 7.16 
(m, 2H), 7.77 (d, 1H); MS(ESI): 418 (M+H)
+
. 
General procedure for the synthesis of all-hydrocarbon stapled peptide (75). Aminomethylated 
polystyrene resin–Rink amide resin LL (0.25mmol, substitution 0.35mmol/g)- was placed in a 
polypropylene reaction vessel and allowed to swell in 10ml of DMF/DCM for 30 minutes followed 
by washing using DMF. The Fmoc group that protects the amine group, bothe on the resin linker and 
each amino acid, was removed with 8ml of piperidine 20% in DMF. For the coupling of non-olefinic 
amino acids, freshly prepared amino acid solution in DMF activated by coupling reagent- HBTU (4 
eq), N-methylmorpholine (8 eq)- was added to the reaction vessel, and the coupling reaction was 
conducted at room temperature for 1h. Each coupling reaction outcome was verified using Kaiser 
reagents. For the coupling of olefinic amino acids, unnatural amino acid (2eq) , HATU (2eq), Cl-
HOBt (2eq) and DIPEA (4eq) were dissolved in DMF and the solution was added to the reaction 
vessel. The reaction was continued for 3h at room temperature. For the reaction of ring closing 
metathesis, the resin-bound peptide with completed sequence was washed by DCM and 1.2-DCE. 
The resin was placed in a two-neck round-bottom flask and treated with a 10mM solution of Grubb’s 
catalyst II generation (0.2eq) in 1,2-dichloroethane. The mixture is stirred under a continuous N2 
flow for 12h at 50°C. At the completion, the resin is washed and dried under vacuum. After the 
removal of Fmoc group from the last residue, the resin-bond peptide washed and dried under vacuum 
overnight. The peptide was cleaved using a TFA cleavage cocktail containing TFA, 
triisopropylsilane, 1,2- ethanendithiol and H2O for 90min at room temperature. Afterwards, the TFA 
solution was concentrated with a gentle stream of N2 and the peptide was precipitated with cold 
diethyl ether. The residue was dried under vacuum to give a brow-black solid, which was purified in 
C-18 reverse phase (20-40μm, 100 Å) using gradient system H2O/acetonitrile. The fractions were 
collected and dried using lyophilizer to give a white solid.  
General procedure for the synthesis of fluorophore-labeled stapled peptide (76). Once the 
peptide sequence was completed, Fmoc group on the last residue was removed. A mixture of  Fmoc-
protected non-α-amino acid, HOBt and NMM in DMF was added, the reaction was kept on rotator 
for 1h at room temperature. The Fmoc-group was removed and fluorescein isothiocyanate in DMF 
was added and the reaction, protected from light, was allowed to continue for 12h at room 
temperature. The resin was cleaved and the residue was purified following the same procedure as for 
compound 75. The final compound was isolated as a yellow solid. 
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Figure 26. Chromatogram showing the purity results for compounds 75 (above) and 76 (below). 
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Figure 27. Mass spectra for compounds 75 (above) and 76 (below). 
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2. Biology 
 
1)  In vitro TG2 inhibition assay  
Kinetic runs were recorded on a UV-visible spectrophotometer at 405nm and 25°C, in a buffer 
composed of 3.33mM CaCl2, 50μM EDTA and 0.1M MOPS (pH 7.0).  All aqueous solutions were 
prepared using deionized water. Each kinetic assay was performed using 180μL of buffer, 5μL of a 
DMSO stock solution of substrate N-Cbz-Glu(γ-p-nitrophenylester)Gly (2.2mM), 10μL of a solution 
of hTG2 at 0.05 U/mL (final concentration of 2.5mU/mL), in the presence of 0-5μL (contingent on 
solubility) of a DMSO stock solution of the test inhibitor. The volume of DMSO was then adjusted 
so that it represented 5% of the final volume. IC50 values were obtained as the negative x-intercept of 
a Dixon plot. 
 
2) In vitro measurement of antioxidant activity 
Solvents of the highest purity grade were used as received. Cumene was twice percolated on an 
alumina column before use. AIBN was recrystallized from methanol. Autoxidation experiments were 
performed in a two-channel oxygen uptake apparatus, based on a Validyne DP 15 differential 
pressure transducer. In a typical experiment, an air-saturated solution of cumene containing AIBN 
was equilibrated with an identical reference solution. After equilibration, and when a constant O2 
consumption was reached, a concentrated solution of test compound (final concentration = 5-15μM) 
was injected in the sample flask. The oxygen consumption in the sample was measured after 
calibration of the apparatus from the differential pressure recorded with time between the two 
channels. 
 
3)  In vitro evaluation of inhibition on Aβ42 self-aggregation by Thioflavin T (ThT) assay 
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP)-pretreated Aβ42 samples (Bachem AG, Switzerland) were 
resolubilized with a CH3CN/0.3 mM Na2CO3/250mM NaOH (48.4:48.4:3.2) mixture to have a stable 
stock solution ([Aβ42]=500μM). Tested inhibitors were dissolved in MeOH and diluted in the assay 
buffer. Experiments were performed by incubating the peptide diluted in 10mM phosphate buffer 
(pH 8.0) containing 10mM NaCl at 30°C (Thermomixer Comfort, Eppendorf, Italy) for 24h (final Aβ 
concentration=50μM) with and without inhibitor. 
Inhibition studies were performed by incubating Aβ42 samples under the assay conditions reported 
above, with and without tested inhibitors. Inhibitors were screened at 10μM in a 0.2:1 ratio with Aβ42. 
After incubation, samples were diluted to a final volume of 2.0mL with 50mM glycine-NaOH buffer 
(pH 8.5) containing 1.5μM ThT. A 300s time scan of fluorescence intensity was performed (λexc=446 
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nm; λem=490 nm), and values at plateau were averaged after subtracting the background fluorescence 
of 1.5μM ThT solution. Blanks containing inhibitor and ThT were also prepared and taken into 
account for quenching and fluorescence properties. The fluorescence intensities were compared and 
the percentage inhibition was calculated. 
 
4)  In vitro GSK3β inhibition assay by UHPLC/UV analysis 
Stock standard solutions of ATP and ADP (1mM) were prepared in buffer A composed of 6mM 
ammonium acetate and 1.6 mM magnesium acetate (pH7.4). Stock standard solutions of 1 mM GSM 
and 100 ng/μL GSK3β were prepared in the buffer A, divided in aliquots and stored at -80°C. The 
test inhibitors were dissolved in DMSO in order to obtain 1 mg/mL stock solutions stored at -20°C.  
The UHPLC/UV analysis was carried out by using a JascoX-LC (Jasco Europe, Cremella, Italy). 
Instrument control, data acquisition and processing were performed using software 
CromNAVControl Center. A reversed phase column (Kinetex 1.7 μm, C8, 50x2.1 mm) was 
equilibrated with a mobile phase consisting of buffer containing 20 mM sodium phosphate and 5 
mM tetra-n-butylammonium/methanol. Optimized chromatographic separation of ATP and ADP was 
carried out under isocratic conditions with a flow rate of 0.4 mL/min. The eluent was monitored at 
260 nm for nucleotide detection.  
The inhibition studies were performed by setting the assay solutions, composed of GSK3β 
(2.5ng/μL), ATP (250μM), GSM (250μM), in presence of increased concentrations of test inhibitors. 
The solutions were incubated at 30°C for 30 min. After incubation, assay reactions were stopped 
adding 40 μL of methanol. An additional 40μL volume of mobile phase buffer for chromatographic 
analysis was further added to the assay reaction. An aliquot of 1μL of the reaction mixture was 
injected into the chromatograph under the chromatographic conditions previously described. The 
peak areas were compared with those obtained in absence of inhibitor. Inhibition curves were 
obtained for each compound by plotting the inhibition percentage versus the logarithm of inhibitor 
concentration in the assay solution. The linear regression parameters were determined for each curve 
and IC50 value was extrapolated. 
 
5)  Cell viability assay using MTS method 
The human tumor cells were cultured in complete growth media at 37°C in CO2/air (5%+95%) 
humidified atmosphere. The assay was performed in triplicate for each test compound. A 50μl of cell 
solution with appropriate concentration were dispensed in 96-well plates and were incubated for 24h. 
Cells were treated with the test compounds at a range of concentration 0.1μM-200μM, prepared as 
50μl solution in culture media. Treated cells were incubated for 72h at 37°C in CO2/air (5%+95%) 
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humidified atmosphere. Afterwards, 20μl of a solution containing MTS reagent/phenazine 
ethosulfate (19:1) were added. After 4h incubation, the absorbance at wavelength 490nm was 
measured using SpectraMax M5 instrument (Molecular Devices). Blank control without cells were 
taken into account as reference for fluorescence-queching effect.  
 
6)  Co-immunoprecipitation assay 
Cells grown in complete culture media were cultured in 100mm dish cells incubated for 24h at 37°C. 
Cell lysis was performed using 300μl lysis Buffer (0.025M Tris, 0.15M NaCl, 0.001M EDTA, 1% 
NP-400, 5% glycerol, pH 7.4) containing 5% of Protease/Phosphatase inhibitor cocktail at 4°C for  
20 minutes. The lysate was centrifuged at 13000xg for 10min at 4°C to afford the pellet which was 
discarded. The supernatant was transferred to a pre-cooled 1.5ml centrifuge tube and the protein 
concentration was measured using BCA assay. 1mg of cell protein was used for co-
immunoprecipitation. 5μg of affinity purified polyclonal antibody was used to capture the bait 
protein -γCOP1. In a 1.5ml microcentrifuge tube the antibody was added to the cell lysate and the 
mixture was incubated overnight at 4°C. Afterwards, Protein A/G agarose beads was added and the 
mixture was allowed to incubate overnight at 4°C. At the completion of incubation, the mixture was 
subject to centrifugation at 1000xg for 5 minute at 4°C to yield a pellet. The supernatant was 
removed carefully, followed by 4 times washing using 1ml of cooled PBS buffer. 
The pellet obtained after co-immunoprecipitation was suspended in 30μl of 2X SDS sample buffer 
containing β-mercaptoethanol, in order to elute the proteins of interest. The sample was heated at 
75°C for 20min and 20μl of sample was loaded on 12% SDS-PAGE gel (Mini-Protean TGX gels). 
Protein separation and blotting on PVDF membrane were performed. The blot was blocked with 
non-fat milk for 4h at 4°C, followed by primary antibody incubation overnight at 4°C. As primary 
antibodies, mouse monoclonal antibody anti-ζCOP1 and antibody anti-γCOP1 have been used for 
immunodetection. Incubation with secondary antibody -goat anti-mouse IgG HPR- was performed at 
room temperature for 1 hour. The signal development was obtained through chemiluminescence. 
After adding the enzyme substrate (Clarity Western ECL substrate), the chemiluminescent signal 
was measured using  LICOR Odyssey FC Imaging system. 
 
7)  Fluorescence cell imaging 
PC3 cells were cultured in complete growth media at 37°C in CO2/air (5%+95%) were seeded in 
triplicate in 96-well plate at concentration of 5000cells/50μl culture media. 50μl drug solution in 
culture media was added to a final concentration of 200μM and the incubation was performed for 
72h at 37°C. Culture media was removed and the cells were rinsed with 100μl PBS (x3) and fixed 
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with 4% para-formaldehyde in PBS for 10min at 37°C. Fixation solution was removed and the cells 
were washed with 100μl PBS (x2). Cell suspension was viewed for fluorescence signal using 
Hermes WiScan (Idea Biomedical). The imaging system is able to generate 10x images. 
 
8)  Docking studies 
Docking simulations were performed using Dock6.5 and Chimera1.10.2 (UCSF Chimera software) 
based on the crystal structure of the ζCOP1/γCOP1 complex bound to Arf1 (PDB code: 3TJZ). The 
PDB file was acquired and edited using GEdit to contain only the ζCOP1 subunit. The coordinate file 
was then read into Chimera, where all hydrogen atoms were erased. Next, the DockPrep command 
was executed, and the resulting structure was saved in mol2 format. The cleaned PDB and prepped 
mol2 files were transferred to the Computational Biology server to generate a molecular surface file. 
Spheres defining the molecular surface of ζCOP1 were generated from an input file and were used to 
create a box that defines the areas of ζCOP1 to be examined with ligand poses. Finally, using the 
charged ζCOP file – and constrained by the parameters of the box – an energy grid was computed. 
Ligands were docked against the energy grid using the determine parameters. The assay was run for 
each of the three ZINC databases (acidic, basic, and neutral) contained in the Computational Biology 
cluster. Each ligand was docked in flexible mode using 500 orientations.  
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